Hemophilia

Genetic MONDO:0018660 Pathograph 12 Show in embeddings browser Bleeding Disorder Coagulation Disorder

Hemophilia is the family of X-linked inherited coagulation factor deficiencies in which a pathogenic variant in F8 or F9 removes one of the two subunits of the intrinsic tenase complex. Factor VIIIa is the cofactor and factor IXa the protease of that single complex, so losing either one disables the same enzymatic step: factor X activation on the activated platelet surface, and with it the propagation-phase burst of thrombin that converts a fragile primary platelet plug into a durable fibrin clot. This is why hemophilia A and hemophilia B were regarded as one disease until Christmas disease was separated from it in 1952, and why they remain clinically indistinguishable at the bedside: the presenting picture in both is bleeding into joints and deep muscle, prolonged or delayed bleeding after injury and surgery, and a severity that tracks residual factor activity rather than which factor is missing. Three features hold across the family and are curated here rather than in each member entry. First, the shared lesion is a complex, not a protein — the mechanism chain is symmetric from either side. Second, severity is graded by residual activity on the same thresholds for both factors (severe under 1%, moderate 1-5%, mild 5-40%), so the family is stratified along an axis that is quantitative and factor-agnostic. Third, the dominant iatrogenic complication of both is the same in kind — a neutralizing alloantibody response to the infused replacement factor that makes replacement therapy fail — although it differs sharply in degree and character between the two factors, and that difference is one of the few places where hemophilia A and B genuinely diverge. This root entry deliberately carries only what holds for hemophilia as a family. The gene-specific molecular pathology, variant spectra, product-specific pharmacology, epidemiology and management are not re-derived here: hemophilia A is fully curated in `Hemophilia_A.yaml` and hemophilia B in `Hemophilia_B.yaml`, and both already declare `Coagulation Disorder` and `Bleeding Disorder` as parents. Hemophilia B Leyden has no entry of its own and is represented here as a subtype only.

Ask OpenScientist

Ask a research question about Hemophilia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
6
Pathophys.
3
Phenotypes
2
Gaps
12
Pathograph
2
Genes
3
Medical Actions
3
Subtypes
3
Trials
2
References
1
Deep Research
🏷

Classifications

Harrison's Part
ONCOLOGY HEMATOLOGY GENETICS ENVIRONMENT DISEASE
👪

Inheritance

1
X-linked recessive HP:0001419
Both F8 (Xq28) and F9 (Xq27.1) are X-linked, so hemophilia manifests predominantly in hemizygous males. Heterozygous females are not uniformly unaffected: skewed X-inactivation can leave a carrier with factor activity in the symptomatic range, and carriers additionally face the reproductive risk of an affected son.
X-linked recessive inheritance
Show evidence (2 references)
PMID:34197690 SUPPORT Human Clinical
"Hemophilia A and B are rare X-linked inherited bleeding disorders caused by complete or partial deficiency in or the absence of coagulation factors VIII and IX."
States the shared X-linked inheritance and the two-factor scope of the family in a single sentence, which is the defining claim of this root entry.
PMID:36800851 SUPPORT Human Clinical
"hemophilia carriers are unique in that they are at risk of giving birth to a severely affected male neonate"
Supports the reproductive consequence of X-linked carriership that distinguishes hemophilia carriers from carriers of the autosomal bleeding disorders.
◆

Subtypes

3
Hemophilia A (Factor VIII Deficiency, Classic Hemophilia) MONDO:0010602
F8 hgnc:3546 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in F8 (hgnc:3546). hgnc:3546 is a gene from the HUGO Gene Nomenclature Committee.
Deficiency of the intrinsic tenase *cofactor*, factor VIII, from pathogenic variants in F8 at Xq28. The more common of the two, and the one for which inhibitor formation against replacement factor is a major and frequent complication. Fully curated in `Hemophilia_A.yaml`, which carries the severity strata, the F8 variant spectrum including the intron 22 inversion, and the FVIII-specific therapeutic landscape.
Hemophilia B (Factor IX Deficiency, Christmas Disease) MONDO:0010604
F9 hgnc:3551 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in F9 (hgnc:3551). hgnc:3551 is a gene from the HUGO Gene Nomenclature Committee.
Deficiency of the intrinsic tenase *protease*, factor IX, from pathogenic variants in F9 at Xq27.1. Clinically indistinguishable from hemophilia A at equivalent residual activity, but distinguished by a much lower inhibitor incidence that carries a disproportionate risk of anaphylaxis and nephrotic syndrome. Fully curated in `Hemophilia_B.yaml`.
Hemophilia B Leyden (Androgen-Responsive F9 Promoter Variant) MONDO:0850054
F9 hgnc:3551 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in F9 (hgnc:3551). hgnc:3551 is a gene from the HUGO Gene Nomenclature Committee.
A cis-regulatory form of hemophilia B in which the lesion lies in the F9 promoter rather than the coding sequence, so the defect is one of transcription rather than of protein structure. Factor IX activity is severely reduced in childhood and then rises around puberty, leaving a phenotype that attenuates with age — the clearest demonstration in this family that the severity axis is a property of residual activity and not a fixed property of the genotype. Has no dismech entry of its own; represented here as a subtype only.
Show evidence (2 references)
PMID:28168417 SUPPORT Human Clinical
"Hemophilia B Leyden is a unique subtype of hemophilia B, characterized by increasing factor IX activity (FIX:C) after puberty and a lower normal range of FIX:C throughout adulthood."
Establishes Leyden as a distinct subtype of hemophilia B defined by an age-dependent rise in factor IX activity rather than by a fixed severity band.
PMID:24138812 SUPPORT Human Clinical
"These mutations, which are clustered at discrete transcription factor binding sites, dynamically alter the developmental expression of F9 in different ways."
Identifies the Leyden lesions as cis-regulatory promoter variants acting on F9 transcription, which is what separates this subtype mechanistically from coding-sequence hemophilia B.
?

Discussions and Knowledge Gaps

2
Should factor XI deficiency and acquired hemophilia be curated as members of this root, given that MONDO places both beneath MONDO:0018660?
KNOWLEDGE GAP OPEN hemophilia_root_scope_fxi_and_acquired
Attached to
pathophysiology#Intrinsic Tenase Subunit Deficiency
MONDO's is_a descendants of MONDO:0018660 include congenital factor XI deficiency (MONDO:0012897 / MONDO:0020587, historically "hemophilia C") and acquired hemophilia (MONDO:0019139, with its A and B forms), but the MONDO textual definition of the same term restricts it to disease "due to factor VIII or IX deficiency". The ontology's hierarchy and its own definition therefore disagree, and this entry follows the definition. The exclusions are mechanistically motivated rather than merely conventional. Factor XI is upstream of the intrinsic tenase complex, not part of it, so factor XI deficiency does not instantiate this root's central mechanism node; it is autosomal rather than X-linked, so it fails the inheritance claim; and its bleeding phenotype is notoriously poorly correlated with factor level, so it fails the severity-by-residual-activity axis that is the second thing this root asserts. Acquired hemophilia fails a different test: its mechanism downstream of factor neutralization is genuinely this root's mechanism, but it is an autoantibody disease of adults with no germline lesion, so it is not an inherited coagulation factor deficiency at all. Notably, acquired hemophilia is closer to the "Alloimmune Inhibitor Response to Replacement Factor" node of this entry than to its trigger node. Recording rather than silently resolving this, because a future curator adding either entity will find MONDO asserting a parentage this entry declines.
If acquired hemophilia is curated later, the natural attachment is a shared mechanism module over factor-neutralization-mediated tenase failure, not membership in this root.
MONDO:0850054 (hemophilia B leyden) is not a descendant of hemophilia B or of hemophilia — should the ontology placement be reported upstream?
KNOWLEDGE GAP OPEN hemophilia_b_leyden_mondo_placement
Attached to
pathophysiology#Residual Factor Activity-Graded Hemostatic Reserve
MONDO:0850054 is asserted only as is_a MONDO:0002243 (hemorrhagic disease), so it sits outside the MONDO:0018660 subtree entirely, even though Orphanet classifies ORPHA:617930 as a subtype of a disorder and every clinical source treats Leyden as a form of hemophilia B. This entry curates it as a subtype on the strength of the clinical literature and flags the ontology gap rather than working around it by choosing a different term. The same subtree is missing the two symptomatic-female-carrier terms in a different way: MONDO:0015787 and MONDO:0015788 are descendants of MONDO:0018660, but dismech has no entry for either, and this root treats symptomatic carriership as part of the inheritance claim rather than as a subtype.
Candidate upstream report to MONDO: add is_a MONDO:0010604 (hemophilia B) to MONDO:0850054.
⚙

Pathophysiology

6
Intrinsic Tenase Subunit Deficiency
A pathogenic variant in F8 or in F9 reduces or abolishes functional factor VIII or factor IX. The two proteins are not redundant partners in separate pathways: they are the cofactor and the protease of one complex, so a lesion in either gene removes one subunit of the same enzyme. This is the point at which hemophilia A and hemophilia B are distinct diseases, and it is the last point at which they are distinct — everything downstream of this node is shared.
intrinsic pathway of blood coagulation GO:0007597 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased intrinsic pathway of blood coagulation, annotated with blood coagulation, intrinsic pathway (GO:0007597). GO:0007597 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Intrinsic Tenase Complex Failure Loss of either subunit prevents assembly of a functional factor VIIIa-factor IXa complex on the activated platelet membrane.
Show evidence (1 reference)
PMID:34197690 SUPPORT Human Clinical
"Hemophilia A and B are rare X-linked inherited bleeding disorders caused by complete or partial deficiency in or the absence of coagulation factors VIII and IX."
Establishes deficiency of either factor VIII or factor IX as the initiating lesion shared by both members of the family.
Intrinsic Tenase Complex Failure
Without a functional factor VIIIa-factor IXa complex, factor X activation on the activated platelet surface proceeds at a small fraction of its normal rate. The node is reached symmetrically: hemophilia A removes the cofactor that accelerates the reaction, hemophilia B removes the protease that performs it. Because the initiation phase of coagulation is driven by tissue factor and is intact, the defect is specifically one of amplification rather than of starting a clot at all.
assembly of the factor VIIIa-factor IXa intrinsic tenase complex GO:0007597 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased assembly of the factor VIIIa-factor IXa intrinsic tenase complex, annotated with blood coagulation, intrinsic pathway (GO:0007597). GO:0007597 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Loss of the Propagation-Phase Thrombin Burst
Show evidence (2 references)
PMID:19563500 SUPPORT Human Clinical
"In the absence of factor VIIIa (as in hemophilia A), the intrinsic tenase complex (factor VIIIa-factor IXa) is unable to generate the additional factor Xa that is required for the burst (propagation) of thrombin generation through the prothrombinase complex (factor Va-factor Xa)"
Names the complex and its two subunits explicitly, and gives the factor VIII arm of the symmetric mechanism this node asserts.
PMID:32809627 SUPPORT Other
"Factor IX serves as a critical component of the intrinsic coagulation pathway, and its deficiency disrupts normal fibrin clot formation, predisposing affected individuals to prolonged or spontaneous bleeding."
Gives the factor IX arm of the same mechanism, so the shared node is supported from both sides rather than generalized from hemophilia A alone.
Loss of the Propagation-Phase Thrombin Burst
Reduced factor Xa output starves the prothrombinase complex and abolishes the large, rapid second wave of thrombin generation that normally follows initiation. The consequence is a clot that forms but does not hold: too little thrombin to build a dense, mechanically stiff and lysis-resistant fibrin network, hence bleeding that is characteristically delayed or recurrent rather than immediate. That this step is shared, rather than inferred from one member, is shown by whole blood studies in which hemophilia A and hemophilia B behave alike.
propagation-phase thrombin generation by the prothrombinase complex GO:0072377 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased propagation-phase thrombin generation by the prothrombinase complex, annotated with blood coagulation, common pathway (GO:0072377). GO:0072377 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Residual Factor Activity-Graded Hemostatic Reserve How much thrombin can still be generated is set by how much functional factor remains, which is what makes severity a continuous quantity.
Hemarthrosis
Intramuscular Hematoma
Persistent Bleeding After Trauma
Show evidence (1 reference)
PMID:11806995 SUPPORT In Vitro
"pharmacologic concentrations of factor VIIa cannot restore normal thrombin generation in hemophilia A and hemophilia B blood in vitro."
Treats hemophilia A and hemophilia B blood as one experimental group with the same thrombin-generation defect, which is the evidence that this node is shared rather than extrapolated.
Residual Factor Activity-Graded Hemostatic Reserve
Hemophilia is graded, not binary. The same activity thresholds are applied to factor VIII and to factor IX — under 1% severe, 1-5% moderate, 5-40% mild — and they predict phenotype well enough to be the basis of classification and of treatment decisions in both members. This is what makes severity a family-level axis rather than a per-gene one, and it is the reason non-factor therapies and gene therapy are evaluated against a target activity level rather than against restoration of the specific missing protein. Hemophilia B Leyden is the instructive exception that proves the rule: the same patient moves up the severity scale with age as promoter activity rises.
Downstream
Persistent Bleeding After Trauma Reserve sufficient to survive daily life but not surgery or major trauma is the mild end of the axis; absent reserve is the severe end, with spontaneous bleeding.
Show evidence (2 references)
PMID:30129541 SUPPORT Human Clinical
"Specific factor assays confirm diagnosis and classify hemophilia according to residual factor activity (mild 5-40%, moderate 1-5%, severe <1%)."
States the severity classification in terms of residual factor activity for hemophilia generically, giving the thresholds that apply to both members.
PMID:32809627 SUPPORT Other
"The severity of bleeding correlates closely with residual factor IX activity, making accurate laboratory assessment essential for disease classification, treatment planning, and long-term risk stratification."
Confirms that the activity-severity relationship, and the use of activity for classification, holds on the factor IX side as well as the factor VIII side.
Alloimmune Inhibitor Response to Replacement Factor
Infused factor concentrate is a foreign protein to a patient whose own gene makes little or none of it, and in a substantial minority it provokes neutralizing IgG that inactivates the infused factor. This is the shared iatrogenic complication of the family and the principal reason replacement therapy fails, but it is also the sharpest point of divergence between the two members: inhibitors arise in roughly a third of severe hemophilia A, and in only a small percentage of hemophilia B, where they instead carry a characteristic risk of anaphylaxis and of nephrotic syndrome during immune tolerance induction. The asymmetry is why this node is curated at the root as a shared *kind* of complication while its frequency and management remain member-specific.
neutralizing anti-factor IgG alloantibody response GO:0002455 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased neutralizing anti-factor IgG alloantibody response, annotated with humoral immune response mediated by circulating immunoglobulin (GO:0002455). GO:0002455 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Refractoriness to Factor Replacement
Show evidence (2 references)
PMID:29482894 SUPPORT Human Clinical
"the most important complication in the treatment of hemophilia A is the development of neutralizing antibodies (inhibitors) against exogenous administered factor VIII (FVIII), which occurs in approximately 30% of all patients with severe hemophilia A"
Establishes the alloimmune inhibitor response, and its frequency, on the hemophilia A side of the family.
PMID:25851415 SUPPORT Human Clinical
"these individuals are also at risk of anaphylaxis, and nephrotic syndrome if they receive immune tolerance induction"
Gives the hemophilia B side, where the inhibitor complication is rarer but carries anaphylaxis and nephrotic syndrome as distinctive hazards.
Refractoriness to Factor Replacement
Once a high-titer inhibitor is present, infused factor is neutralized before it can participate in tenase assembly, so the patient reverts to the untreated hemostatic phenotype despite treatment. Management shifts to bypassing agents, immune tolerance induction, or non-factor prophylaxis that does not present the missing factor to the immune system at all.
Downstream
Residual Factor Activity-Graded Hemostatic Reserve Neutralization of the infused factor returns effective circulating activity to the patient's untreated baseline, so an inhibitor moves the patient back down the same severity axis that replacement therapy moves them up. This is why the inhibitor arm is not a separate disease process but a reversible re-entry into the shared one.
Show evidence (1 reference)
PMID:29482894 SUPPORT Human Clinical
"This antibody response renders FVIII replacement therapy ineffective, thereby increasing the risk for uncontrollable bleeding and morbidity, decreasing quality of life and increasing healthcare costs."
Describes the refractory state that follows inhibitor development and its clinical consequences.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hemophilia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

3
Blood 1
Hemarthrosis Joint hemorrhage HP:0005261 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Joint hemorrhage (HP:0005261). HP:0005261 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34197690 SUPPORT Human Clinical
"Recurrent joint bleeding (hemarthrosis) is the most frequent clinical manifestation of severe hemophilia."
Stated for severe hemophilia as a whole rather than for one member, which is what makes it a root-level phenotype.
Musculoskeletal 1
Intramuscular Hematoma HP:0012233 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intramuscular hematoma (HP:0012233). HP:0012233 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301578 SUPPORT Other
"individuals may average up to two to five spontaneous bleeding episodes each month including spontaneous joint bleeds or deep-muscle hematomas"
GeneReviews documents deep-muscle hematoma alongside joint bleeding as the characteristic spontaneous bleeding pattern of severe disease.
Other 1
Persistent Bleeding After Trauma HP:0001934 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Persistent bleeding after trauma (HP:0001934). HP:0001934 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:27890816 SUPPORT Human Clinical
"Hemophilia is a congenital clotting factor deficiency characterized by spontaneous and trauma-related bleeding."
Characterizes hemophilia generically by spontaneous and trauma-related bleeding.
PMID:20301578 SUPPORT Other
"prolonged bleeding after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing"
Describes the delayed and recurrent character of the bleeding, which is the clinical signature of a propagation-phase rather than an initiation-phase defect.
🧬

Genetic Associations

2
F8 (Pathogenic Variants)
Gene: F8 hgnc:3546 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is F8 (hgnc:3546). hgnc:3546 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:34197690 SUPPORT Human Clinical
"Hemophilia A and B are rare X-linked inherited bleeding disorders caused by complete or partial deficiency in or the absence of coagulation factors VIII and IX."
Attributes hemophilia A to factor VIII deficiency within the two-gene scope of this root entry.
F9 (Pathogenic Variants)
Gene: F9 hgnc:3551 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is F9 (hgnc:3551). hgnc:3551 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
CGGV:assertion_3d56d08d-48d0-4523-b433-dbd44c5b9e45-2019-05-22T190226.728Z SUPPORT Other
"F9 | HGNC:3551 | hemophilia B | MONDO:0010604 | XL | Definitive"
ClinGen classifies the F9-hemophilia B relationship as definitive with X-linked inheritance, one of the two gene-disease relationships this family unites.
💊

Medical Actions

3
Prophylactic Clotting Factor Replacement
Action: Protein Replacement TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Protein Replacement Therapy (NCIT:C16221). NCIT:C16221 is a clinical intervention from the NCI Thesaurus. NCIT:C16221
Scheduled infusion of the deficient factor to hold trough activity above the spontaneous-bleeding threshold, rather than treating bleeds as they occur. This is the shared standard of care across the family: the same recommendation, from the same guideline, is issued for severe and moderately severe disease of both types, which is a direct consequence of severity being defined by residual activity.
Mechanism Target:
RESTORES Residual Factor Activity-Graded Hemostatic Reserve — Replacement raises circulating factor activity, moving the patient up the same severity axis that defines the family.
Show evidence (1 reference)
PMID:39043543 SUPPORT Human Clinical
"Strong recommendations were issued for prophylactic over episodic treatment for severe and moderately severe hemophilia A and B."
A single GRADE-based guideline issues the same strong prophylaxis recommendation for both members, which is why this treatment belongs at the family level.
Gene Therapy
Action: gene therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is gene therapy (NCIT:C15238). NCIT:C15238 is a clinical intervention from the NCI Thesaurus. Ontology label: Gene Therapy NCIT:C15238
A single infusion of an AAV vector directing hepatocyte expression of the missing factor, developed in parallel for both members of the family and evaluated in both against achieved factor activity. Product-specific detail belongs to the member entries.
Mechanism Target:
RESTORES Intrinsic Tenase Subunit Deficiency — Supplies a functional transgene copy so the deficient subunit is synthesized endogenously, addressing the initiating lesion rather than its consequences.
Show evidence (1 reference)
PMID:36103998 SUPPORT Human Clinical
"For almost three decades, hemophilia A (HA) and hemophilia B (HB) have served as model disorders for the development of gene therapy."
Confirms that gene therapy has been developed for both members in parallel, which is what makes it a family-level rather than a member-specific treatment.
Hemostatic Rebalancing Prophylaxis
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: fitusiran NCIT:C169984 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses fitusiran (NCIT:C169984). NCIT:C169984 is a therapeutic agent from the NCI Thesaurus. concizumab NCIT:C166914 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses concizumab (NCIT:C166914). NCIT:C166914 is a therapeutic agent from the NCI Thesaurus. marstacimab NCIT:C166436 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses marstacimab (NCIT:C166436). NCIT:C166436 is a therapeutic agent from the NCI Thesaurus.
Subcutaneous prophylaxis that restores thrombin generation by lowering a natural anticoagulant rather than by supplying the missing factor: fitusiran, a small interfering RNA that knocks down antithrombin, and concizumab and marstacimab, monoclonal antibodies against tissue factor pathway inhibitor. This class belongs at the root rather than on either member, and the reason is the same lumping logic that justifies this entry. Emicizumab is correctly curated on `Hemophilia_A.yaml` because it is a bispecific FVIIIa *mimetic* — it substitutes for the missing cofactor and therefore cannot help a patient missing the protease instead. Rebalancing agents act downstream of the intrinsic tenase step entirely, on the anticoagulant side of the hemostatic balance, so they are indifferent to which subunit is absent. Their pivotal trials enrolled hemophilia A and hemophilia B together, and separately enrolled patients with and without inhibitors, which is an experimental design only a genuinely factor-agnostic mechanism permits. Because they do not present the deficient factor to the immune system, they also remain effective once an inhibitor has made replacement therapy fail — which is what gives this entry's `Refractoriness to Factor Replacement` node a therapy at all. The class is not free of risk: rebalancing narrows the margin in the prothrombotic direction, and thromboembolic events have been reported in both programmes.
Mechanism Target:
RESTORES Loss of the Propagation-Phase Thrombin Burst — Lowering antithrombin or TFPI shifts the procoagulant-anticoagulant balance so that the thrombin generated by an intact extrinsic route is no longer quenched, recovering hemostatic thrombin output without repairing the tenase complex.
Show evidence (1 reference)
PMID:40584300 SUPPORT Human Clinical
"Marstacimab restores thrombin generation via the extrinsic pathway, bypassing intrinsic pathway deficiencies and offering prophylactic benefit independent of inhibitor status."
States exactly the mechanism this edge asserts, and states that it operates by bypassing rather than repairing the intrinsic defect.
BYPASSES Refractoriness to Factor Replacement — Because no exogenous factor VIII or factor IX is administered, a neutralizing inhibitor has nothing to neutralize, so hemostatic benefit survives the state that abolishes the benefit of replacement therapy.
Show evidence (1 reference)
PMID:37003287 SUPPORT Human Clinical
"Subcutaneous fitusiran prophylaxis resulted in statistically significant reductions in annualised bleeding rate in participants with haemophilia A or haemophilia B with inhibitors, with two-thirds of participants having zero bleeds."
Demonstrates efficacy specifically in the inhibitor population, i.e. in exactly the patients for whom factor replacement has been rendered ineffective.
Show evidence (4 references)
PMID:37003287 SUPPORT Human Clinical
"Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, targets antithrombin to rebalance haemostasis in people with haemophilia A or haemophilia B, irrespective of inhibitor status."
Names the modality, the molecular target, and the rebalancing mechanism, and states the factor-agnostic and inhibitor-agnostic scope that makes this a family-level rather than a member-level therapy.
PMID:37003278 SUPPORT Human Clinical
"Fitusiran prophylaxis shows haemostatic efficacy in both haemophilia A and haemophilia B, and therefore has the potential to be transformative in the management of all people with haemophilia."
The companion trial in the non-inhibitor population, establishing that efficacy spans both members independently of inhibitor status rather than only in the inhibitor setting.
PMID:37646676 SUPPORT Human Clinical
"Concizumab is an anti-tissue factor pathway inhibitor monoclonal antibody designed to achieve hemostasis in all hemophilia types, with subcutaneous administration."
Establishes the second molecular route into the same class, and its explicit design intent of working across all hemophilia types.
+ 1 more reference
🔬

Clinical Trials

3
NCT03417102 PHASE_III COMPLETED
ATLAS-INH. Randomised open-label phase 3 trial of monthly subcutaneous fitusiran prophylaxis versus on-demand bypassing agents in severe hemophilia A or B with inhibitors.
Target Phenotypes: Joint hemorrhage HP:0005261 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Joint hemorrhage (HP:0005261). HP:0005261 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT03417102 SUPPORT Human Clinical
"The purpose of this study was to determine the frequency of bleeding episodes in participants receiving fitusiran as prophylactic treatment of hemophilia compared to participants who were assigned to continue with their regular medication."
Registry record for the pivotal inhibitor-population trial of the rebalancing class curated at this root.
NCT03754790 PHASE_III COMPLETED
ATLAS-OLE. Open-label long-term extension of fitusiran in hemophilia A or B, with or without inhibitors (281 participants). The enrolment criteria span both members of this family and both inhibitor states, which is why the trial is recorded at the root rather than on either member entry.
Show evidence (1 reference)
clinicaltrials:NCT03754790 SUPPORT Human Clinical
"To characterize the long-term safety and tolerability of fitusiran"
Registry record for the long-term extension whose population spans hemophilia A and B with and without inhibitors.
NCT04083781 PHASE_III COMPLETED
explorer7. Phase 3 trial of daily subcutaneous concizumab prophylaxis in haemophilia A or B with inhibitors, reported in PMID:37646676.
Target Phenotypes: Joint hemorrhage HP:0005261 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Joint hemorrhage (HP:0005261). HP:0005261 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT04083781 SUPPORT Human Clinical
"This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B with inhibitors."
Registry record confirming the trial population spans both members of the family in the inhibitor setting.
{ }

Source YAML

click to show 
name: Hemophilia
creation_date: '2026-08-20T00:00:00Z'
category: Genetic
description: >
  Hemophilia is the family of X-linked inherited coagulation factor deficiencies in
  which a pathogenic variant in F8 or F9 removes one of the two subunits of the
  intrinsic tenase complex. Factor VIIIa is the cofactor and factor IXa the protease
  of that single complex, so losing either one disables the same enzymatic step:
  factor X activation on the activated platelet surface, and with it the
  propagation-phase burst of thrombin that converts a fragile primary platelet plug
  into a durable fibrin clot. This is why hemophilia A and hemophilia B were regarded
  as one disease until Christmas disease was separated from it in 1952, and why they
  remain clinically indistinguishable at the bedside: the presenting picture in both
  is bleeding into joints and deep muscle, prolonged or delayed bleeding after injury
  and surgery, and a severity that tracks residual factor activity rather than which
  factor is missing.

  Three features hold across the family and are curated here rather than in each
  member entry. First, the shared lesion is a complex, not a protein — the mechanism
  chain is symmetric from either side. Second, severity is graded by residual
  activity on the same thresholds for both factors (severe under 1%, moderate 1-5%,
  mild 5-40%), so the family is stratified along an axis that is quantitative and
  factor-agnostic. Third, the dominant iatrogenic complication of both is the same in
  kind — a neutralizing alloantibody response to the infused replacement factor that
  makes replacement therapy fail — although it differs sharply in degree and
  character between the two factors, and that difference is one of the few places
  where hemophilia A and B genuinely diverge.

  This root entry deliberately carries only what holds for hemophilia as a family. The
  gene-specific molecular pathology, variant spectra, product-specific pharmacology,
  epidemiology and management are not re-derived here: hemophilia A is fully curated
  in `Hemophilia_A.yaml` and hemophilia B in `Hemophilia_B.yaml`, and both already
  declare `Coagulation Disorder` and `Bleeding Disorder` as parents. Hemophilia B
  Leyden has no entry of its own and is represented here as a subtype only.
disease_term:
  preferred_term: hemophilia
  term:
    id: MONDO:0018660
    label: hemophilia
synonyms:
- haemophilia
- congenital hemophilia
- inherited coagulation factor VIII or IX deficiency
parents:
- Bleeding Disorder
- Coagulation Disorder
has_subtypes:
- name: Hemophilia A
  display_name: Hemophilia A (Factor VIII Deficiency, Classic Hemophilia)
  classification: deficient coagulation factor
  description: >-
    Deficiency of the intrinsic tenase *cofactor*, factor VIII, from pathogenic
    variants in F8 at Xq28. The more common of the two, and the one for which
    inhibitor formation against replacement factor is a major and frequent
    complication. Fully curated in `Hemophilia_A.yaml`, which carries the severity
    strata, the F8 variant spectrum including the intron 22 inversion, and the
    FVIII-specific therapeutic landscape.
  subtype_term:
    preferred_term: hemophilia A
    term:
      id: MONDO:0010602
      label: hemophilia A
  genes:
  - preferred_term: F8
    term:
      id: hgnc:3546
      label: F8
- name: Hemophilia B
  display_name: Hemophilia B (Factor IX Deficiency, Christmas Disease)
  classification: deficient coagulation factor
  description: >-
    Deficiency of the intrinsic tenase *protease*, factor IX, from pathogenic
    variants in F9 at Xq27.1. Clinically indistinguishable from hemophilia A at
    equivalent residual activity, but distinguished by a much lower inhibitor
    incidence that carries a disproportionate risk of anaphylaxis and nephrotic
    syndrome. Fully curated in `Hemophilia_B.yaml`.
  subtype_term:
    preferred_term: hemophilia B
    term:
      id: MONDO:0010604
      label: hemophilia B
  genes:
  - preferred_term: F9
    term:
      id: hgnc:3551
      label: F9
- name: Hemophilia B Leyden
  display_name: Hemophilia B Leyden (Androgen-Responsive F9 Promoter Variant)
  classification: deficient coagulation factor
  description: >-
    A cis-regulatory form of hemophilia B in which the lesion lies in the F9
    promoter rather than the coding sequence, so the defect is one of transcription
    rather than of protein structure. Factor IX activity is severely reduced in
    childhood and then rises around puberty, leaving a phenotype that attenuates with
    age — the clearest demonstration in this family that the severity axis is a
    property of residual activity and not a fixed property of the genotype. Has no
    dismech entry of its own; represented here as a subtype only.
  subtype_term:
    preferred_term: hemophilia B leyden
    term:
      id: MONDO:0850054
      label: hemophilia B leyden
  genes:
  - preferred_term: F9
    term:
      id: hgnc:3551
      label: F9
  evidence:
  - reference: PMID:28168417
    reference_title: "First case report of hemophilia B Leyden in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hemophilia B Leyden is a unique subtype of hemophilia B, characterized by increasing factor IX activity (FIX:C) after puberty and a lower normal range of FIX:C throughout adulthood."
    explanation: >-
      Establishes Leyden as a distinct subtype of hemophilia B defined by an
      age-dependent rise in factor IX activity rather than by a fixed severity band.
  - reference: PMID:24138812
    reference_title: "Hemophilia B Leyden and once mysterious cis-regulatory mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These mutations, which are clustered at discrete transcription factor binding sites, dynamically alter the developmental expression of F9 in different ways."
    explanation: >-
      Identifies the Leyden lesions as cis-regulatory promoter variants acting on F9
      transcription, which is what separates this subtype mechanistically from
      coding-sequence hemophilia B.
inheritance:
- name: X-linked recessive
  description: >-
    Both F8 (Xq28) and F9 (Xq27.1) are X-linked, so hemophilia manifests
    predominantly in hemizygous males. Heterozygous females are not uniformly
    unaffected: skewed X-inactivation can leave a carrier with factor activity in the
    symptomatic range, and carriers additionally face the reproductive risk of an
    affected son.
  inheritance_term:
    preferred_term: X-linked recessive inheritance
    term:
      id: HP:0001419
      label: X-linked recessive inheritance
  evidence:
  - reference: PMID:34197690
    reference_title: "Hemophilic arthropathy: Current knowledge and future perspectives."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hemophilia A and B are rare X-linked inherited bleeding disorders caused by complete or partial deficiency in or the absence of coagulation factors VIII and IX."
    explanation: >-
      States the shared X-linked inheritance and the two-factor scope of the family in
      a single sentence, which is the defining claim of this root entry.
  - reference: PMID:36800851
    reference_title: "Von Willebrand Disease, Hemophilia, and Other Inherited Bleeding Disorders in Pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hemophilia carriers are unique in that they are at risk of giving birth to a severely affected male neonate"
    explanation: >-
      Supports the reproductive consequence of X-linked carriership that distinguishes
      hemophilia carriers from carriers of the autosomal bleeding disorders.
pathophysiology:
- name: Intrinsic Tenase Subunit Deficiency
  biological_scale: MOLECULAR
  description: >
    A pathogenic variant in F8 or in F9 reduces or abolishes functional factor VIII or
    factor IX. The two proteins are not redundant partners in separate pathways: they
    are the cofactor and the protease of one complex, so a lesion in either gene
    removes one subunit of the same enzyme. This is the point at which hemophilia A
    and hemophilia B are distinct diseases, and it is the last point at which they are
    distinct — everything downstream of this node is shared.
  biological_processes:
  - preferred_term: intrinsic pathway of blood coagulation
    term:
      id: GO:0007597
      label: blood coagulation, intrinsic pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:34197690
    reference_title: "Hemophilic arthropathy: Current knowledge and future perspectives."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hemophilia A and B are rare X-linked inherited bleeding disorders caused by complete or partial deficiency in or the absence of coagulation factors VIII and IX."
    explanation: >-
      Establishes deficiency of either factor VIII or factor IX as the initiating
      lesion shared by both members of the family.
  downstream:
  - target: Intrinsic Tenase Complex Failure
    causal_link_type: DIRECT
    description: >-
      Loss of either subunit prevents assembly of a functional factor VIIIa-factor IXa
      complex on the activated platelet membrane.
- name: Intrinsic Tenase Complex Failure
  biological_scale: MOLECULAR
  description: >
    Without a functional factor VIIIa-factor IXa complex, factor X activation on the
    activated platelet surface proceeds at a small fraction of its normal rate. The
    node is reached symmetrically: hemophilia A removes the cofactor that accelerates
    the reaction, hemophilia B removes the protease that performs it. Because the
    initiation phase of coagulation is driven by tissue factor and is intact, the
    defect is specifically one of amplification rather than of starting a clot at all.
  biological_processes:
  - preferred_term: assembly of the factor VIIIa-factor IXa intrinsic tenase complex
    term:
      id: GO:0007597
      label: blood coagulation, intrinsic pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:19563500
    reference_title: "Thrombin generation and bleeding in haemophilia A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the absence of factor VIIIa (as in hemophilia A), the intrinsic tenase complex (factor VIIIa-factor IXa) is unable to generate the additional factor Xa that is required for the burst (propagation) of thrombin generation through the prothrombinase complex (factor Va-factor Xa)"
    explanation: >-
      Names the complex and its two subunits explicitly, and gives the factor VIII arm
      of the symmetric mechanism this node asserts.
  - reference: PMID:32809627
    reference_title: "Hemophilia B."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Factor IX serves as a critical component of the intrinsic coagulation pathway, and its deficiency disrupts normal fibrin clot formation, predisposing affected individuals to prolonged or spontaneous bleeding."
    explanation: >-
      Gives the factor IX arm of the same mechanism, so the shared node is supported
      from both sides rather than generalized from hemophilia A alone.
  downstream:
  - target: Loss of the Propagation-Phase Thrombin Burst
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19563500
      reference_title: "Thrombin generation and bleeding in haemophilia A."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the intrinsic tenase complex (factor VIIIa-factor IXa) is unable to generate the additional factor Xa that is required for the burst (propagation) of thrombin generation"
      explanation: >-
        Links failure of the tenase complex directly to loss of the propagation-phase
        thrombin burst.
- name: Loss of the Propagation-Phase Thrombin Burst
  biological_scale: MOLECULAR
  description: >
    Reduced factor Xa output starves the prothrombinase complex and abolishes the
    large, rapid second wave of thrombin generation that normally follows initiation.
    The consequence is a clot that forms but does not hold: too little thrombin to
    build a dense, mechanically stiff and lysis-resistant fibrin network, hence
    bleeding that is characteristically delayed or recurrent rather than immediate.
    That this step is shared, rather than inferred from one member, is shown by whole
    blood studies in which hemophilia A and hemophilia B behave alike.
  biological_processes:
  - preferred_term: propagation-phase thrombin generation by the prothrombinase complex
    term:
      id: GO:0072377
      label: blood coagulation, common pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:11806995
    reference_title: "Mechanism of factor VIIa-dependent coagulation in hemophilia blood."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "pharmacologic concentrations of factor VIIa cannot restore normal thrombin generation in hemophilia A and hemophilia B blood in vitro."
    explanation: >-
      Treats hemophilia A and hemophilia B blood as one experimental group with the
      same thrombin-generation defect, which is the evidence that this node is shared
      rather than extrapolated.
  downstream:
  - target: Residual Factor Activity-Graded Hemostatic Reserve
    causal_link_type: DIRECT
    description: >-
      How much thrombin can still be generated is set by how much functional factor
      remains, which is what makes severity a continuous quantity.
  - target: Hemarthrosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - failure to stabilize hemostasis in the synovial vasculature under joint loading
    evidence:
    - reference: PMID:27890816
      reference_title: "Pathophysiology of hemophilic arthropathy and potential targets for therapy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Spontaneous bleeding shows a predilection for joints, and repeated hemarthroses lead to a disabling condition called hemophilic arthropathy."
      explanation: >-
        Identifies the joint as the preferential site of the bleeding that follows the
        hemostatic defect, stated for hemophilia as a whole.
  - target: Intramuscular Hematoma
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - unchecked bleeding into deep muscle compartments after minor or unrecognized trauma
  - target: Persistent Bleeding After Trauma
    causal_link_type: DIRECT
- name: Residual Factor Activity-Graded Hemostatic Reserve
  biological_scale: ORGANISM
  description: >
    Hemophilia is graded, not binary. The same activity thresholds are applied to
    factor VIII and to factor IX — under 1% severe, 1-5% moderate, 5-40% mild — and
    they predict phenotype well enough to be the basis of classification and of
    treatment decisions in both members. This is what makes severity a family-level
    axis rather than a per-gene one, and it is the reason non-factor therapies and
    gene therapy are evaluated against a target activity level rather than against
    restoration of the specific missing protein. Hemophilia B Leyden is the instructive
    exception that proves the rule: the same patient moves up the severity scale with
    age as promoter activity rises.
  evidence:
  - reference: PMID:30129541
    reference_title: "Consensus Statement of the Indian Academy of Pediatrics in Diagnosis and Management of Hemophilia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Specific factor assays confirm diagnosis and classify hemophilia according to residual factor activity (mild 5-40%, moderate 1-5%, severe <1%)."
    explanation: >-
      States the severity classification in terms of residual factor activity for
      hemophilia generically, giving the thresholds that apply to both members.
  - reference: PMID:32809627
    reference_title: "Hemophilia B."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The severity of bleeding correlates closely with residual factor IX activity, making accurate laboratory assessment essential for disease classification, treatment planning, and long-term risk stratification."
    explanation: >-
      Confirms that the activity-severity relationship, and the use of activity for
      classification, holds on the factor IX side as well as the factor VIII side.
  downstream:
  - target: Persistent Bleeding After Trauma
    causal_link_type: DIRECT
    description: >-
      Reserve sufficient to survive daily life but not surgery or major trauma is the
      mild end of the axis; absent reserve is the severe end, with spontaneous bleeding.
- name: Alloimmune Inhibitor Response to Replacement Factor
  biological_scale: ORGANISM
  description: >
    Infused factor concentrate is a foreign protein to a patient whose own gene makes
    little or none of it, and in a substantial minority it provokes neutralizing IgG
    that inactivates the infused factor. This is the shared iatrogenic complication of
    the family and the principal reason replacement therapy fails, but it is also the
    sharpest point of divergence between the two members: inhibitors arise in roughly
    a third of severe hemophilia A, and in only a small percentage of hemophilia B,
    where they instead carry a characteristic risk of anaphylaxis and of nephrotic
    syndrome during immune tolerance induction. The asymmetry is why this node is
    curated at the root as a shared *kind* of complication while its frequency and
    management remain member-specific.
  biological_processes:
  - preferred_term: neutralizing anti-factor IgG alloantibody response
    term:
      id: GO:0002455
      label: humoral immune response mediated by circulating immunoglobulin
    modifier: INCREASED
  evidence:
  - reference: PMID:29482894
    reference_title: "Review of immune tolerance induction in hemophilia A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the most important complication in the treatment of hemophilia A is the development of neutralizing antibodies (inhibitors) against exogenous administered factor VIII (FVIII), which occurs in approximately 30% of all patients with severe hemophilia A"
    explanation: >-
      Establishes the alloimmune inhibitor response, and its frequency, on the
      hemophilia A side of the family.
  - reference: PMID:25851415
    reference_title: "Hemophilia B: molecular pathogenesis and mutation analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "these individuals are also at risk of anaphylaxis, and nephrotic syndrome if they receive immune tolerance induction"
    explanation: >-
      Gives the hemophilia B side, where the inhibitor complication is rarer but
      carries anaphylaxis and nephrotic syndrome as distinctive hazards.
  downstream:
  - target: Refractoriness to Factor Replacement
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29482894
      reference_title: "Review of immune tolerance induction in hemophilia A."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This antibody response renders FVIII replacement therapy ineffective, thereby increasing the risk for uncontrollable bleeding and morbidity, decreasing quality of life and increasing healthcare costs."
      explanation: >-
        Links the neutralizing antibody response directly to loss of efficacy of
        replacement therapy and to worse bleeding outcomes.
- name: Refractoriness to Factor Replacement
  biological_scale: ORGANISM
  description: >-
    Once a high-titer inhibitor is present, infused factor is neutralized before it can
    participate in tenase assembly, so the patient reverts to the untreated hemostatic
    phenotype despite treatment. Management shifts to bypassing agents, immune
    tolerance induction, or non-factor prophylaxis that does not present the missing
    factor to the immune system at all.
  evidence:
  - reference: PMID:29482894
    reference_title: "Review of immune tolerance induction in hemophilia A."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This antibody response renders FVIII replacement therapy ineffective, thereby increasing the risk for uncontrollable bleeding and morbidity, decreasing quality of life and increasing healthcare costs."
    explanation: >-
      Describes the refractory state that follows inhibitor development and its
      clinical consequences.
  downstream:
  - target: Residual Factor Activity-Graded Hemostatic Reserve
    causal_link_type: DIRECT
    description: >-
      Neutralization of the infused factor returns effective circulating activity to
      the patient's untreated baseline, so an inhibitor moves the patient back down
      the same severity axis that replacement therapy moves them up. This is why the
      inhibitor arm is not a separate disease process but a reversible re-entry into
      the shared one.
    evidence:
    - reference: PMID:29482894
      reference_title: "Review of immune tolerance induction in hemophilia A."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This antibody response renders FVIII replacement therapy ineffective, thereby increasing the risk for uncontrollable bleeding and morbidity"
      explanation: >-
        Loss of efficacy of replacement therapy, with a consequent rise in bleeding
        risk, is the return to the untreated hemostatic reserve this edge asserts.
phenotypes:
- name: Hemarthrosis
  category: Musculoskeletal
  diagnostic: true
  description: >-
    Bleeding into the synovial joint space, the single most characteristic
    manifestation of severe hemophilia of either type, and the driver of the
    progressive hemophilic arthropathy that dominates long-term morbidity.
  phenotype_term:
    preferred_term: Joint hemorrhage
    term:
      id: HP:0005261
      label: Joint hemorrhage
  evidence:
  - reference: PMID:34197690
    reference_title: "Hemophilic arthropathy: Current knowledge and future perspectives."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recurrent joint bleeding (hemarthrosis) is the most frequent clinical manifestation of severe hemophilia."
    explanation: >-
      Stated for severe hemophilia as a whole rather than for one member, which is what
      makes it a root-level phenotype.
- name: Intramuscular Hematoma
  category: Musculoskeletal
  description: >-
    Deep bleeding into muscle compartments, classically iliopsoas, quadriceps and calf,
    which can compress nerves or produce compartment syndrome. Together with joint
    bleeding it defines the deep-tissue bleeding pattern that distinguishes a
    coagulation-factor defect from a platelet or vessel-wall defect.
  phenotype_term:
    preferred_term: Intramuscular hematoma
    term:
      id: HP:0012233
      label: Intramuscular hematoma
  evidence:
  - reference: PMID:20301578
    reference_title: "Hemophilia A."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "individuals may average up to two to five spontaneous bleeding episodes each month including spontaneous joint bleeds or deep-muscle hematomas"
    explanation: >-
      GeneReviews documents deep-muscle hematoma alongside joint bleeding as the
      characteristic spontaneous bleeding pattern of severe disease.
- name: Persistent Bleeding After Trauma
  category: Hematologic
  description: >-
    Prolonged, delayed or recurrent bleeding after injury, tooth extraction or surgery.
    Because the initiation phase of coagulation is intact and only propagation fails,
    bleeding characteristically stops and then restarts rather than failing to stop at
    all, which is why mild disease can go unrecognized until a surgical challenge.
  phenotype_term:
    preferred_term: Persistent bleeding after trauma
    term:
      id: HP:0001934
      label: Persistent bleeding after trauma
  evidence:
  - reference: PMID:27890816
    reference_title: "Pathophysiology of hemophilic arthropathy and potential targets for therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hemophilia is a congenital clotting factor deficiency characterized by spontaneous and trauma-related bleeding."
    explanation: >-
      Characterizes hemophilia generically by spontaneous and trauma-related bleeding.
  - reference: PMID:20301578
    reference_title: "Hemophilia A."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "prolonged bleeding after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing"
    explanation: >-
      Describes the delayed and recurrent character of the bleeding, which is the
      clinical signature of a propagation-phase rather than an initiation-phase defect.
genetic:
- name: F8
  notes: >-
    The gene of hemophilia A, encoding the intrinsic tenase cofactor factor VIII. The
    variant spectrum is curated in `Hemophilia_A.yaml` and is not repeated here.
  gene_term:
    preferred_term: F8
    term:
      id: hgnc:3546
      label: F8
  association: Pathogenic Variants
  evidence:
  - reference: PMID:34197690
    reference_title: "Hemophilic arthropathy: Current knowledge and future perspectives."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hemophilia A and B are rare X-linked inherited bleeding disorders caused by complete or partial deficiency in or the absence of coagulation factors VIII and IX."
    explanation: >-
      Attributes hemophilia A to factor VIII deficiency within the two-gene scope of
      this root entry.
- name: F9
  notes: >-
    The gene of hemophilia B, encoding the intrinsic tenase protease factor IX. Both
    coding variants and the cis-regulatory promoter variants of hemophilia B Leyden act
    through this locus.
  gene_term:
    preferred_term: F9
    term:
      id: hgnc:3551
      label: F9
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_3d56d08d-48d0-4523-b433-dbd44c5b9e45-2019-05-22T190226.728Z
    reference_title: "F9 / hemophilia B (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "F9 | HGNC:3551 | hemophilia B | MONDO:0010604 | XL | Definitive"
    explanation: >-
      ClinGen classifies the F9-hemophilia B relationship as definitive with X-linked
      inheritance, one of the two gene-disease relationships this family unites.
treatments:
- name: Prophylactic Clotting Factor Replacement
  description: >-
    Scheduled infusion of the deficient factor to hold trough activity above the
    spontaneous-bleeding threshold, rather than treating bleeds as they occur. This is
    the shared standard of care across the family: the same recommendation, from the
    same guideline, is issued for severe and moderately severe disease of both types,
    which is a direct consequence of severity being defined by residual activity.
  treatment_term:
    preferred_term: Protein Replacement Therapy
    term:
      id: NCIT:C16221
      label: Protein Replacement Therapy
  therapeutic_modality: PROTEIN_REPLACEMENT
  target_mechanisms:
  - target: Residual Factor Activity-Graded Hemostatic Reserve
    treatment_effect: RESTORES
    description: >-
      Replacement raises circulating factor activity, moving the patient up the same
      severity axis that defines the family.
  evidence:
  - reference: PMID:39043543
    reference_title: "International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Strong recommendations were issued for prophylactic over episodic treatment for severe and moderately severe hemophilia A and B."
    explanation: >-
      A single GRADE-based guideline issues the same strong prophylaxis recommendation
      for both members, which is why this treatment belongs at the family level.
- name: Gene Therapy
  description: >-
    A single infusion of an AAV vector directing hepatocyte expression of the missing
    factor, developed in parallel for both members of the family and evaluated in both
    against achieved factor activity. Product-specific detail belongs to the member
    entries.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  therapeutic_modality: GENE_THERAPY
  target_mechanisms:
  - target: Intrinsic Tenase Subunit Deficiency
    treatment_effect: RESTORES
    description: >-
      Supplies a functional transgene copy so the deficient subunit is synthesized
      endogenously, addressing the initiating lesion rather than its consequences.
  evidence:
  - reference: PMID:36103998
    reference_title: "Adeno-Associated Virus Gene Therapy for Hemophilia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For almost three decades, hemophilia A (HA) and hemophilia B (HB) have served as model disorders for the development of gene therapy."
    explanation: >-
      Confirms that gene therapy has been developed for both members in parallel, which
      is what makes it a family-level rather than a member-specific treatment.
- name: Hemostatic Rebalancing Prophylaxis
  description: >
    Subcutaneous prophylaxis that restores thrombin generation by lowering a natural
    anticoagulant rather than by supplying the missing factor: fitusiran, a small
    interfering RNA that knocks down antithrombin, and concizumab and marstacimab,
    monoclonal antibodies against tissue factor pathway inhibitor.

    This class belongs at the root rather than on either member, and the reason is the
    same lumping logic that justifies this entry. Emicizumab is correctly curated on
    `Hemophilia_A.yaml` because it is a bispecific FVIIIa *mimetic* — it substitutes for
    the missing cofactor and therefore cannot help a patient missing the protease
    instead. Rebalancing agents act downstream of the intrinsic tenase step entirely,
    on the anticoagulant side of the hemostatic balance, so they are indifferent to
    which subunit is absent. Their pivotal trials enrolled hemophilia A and hemophilia
    B together, and separately enrolled patients with and without inhibitors, which is
    an experimental design only a genuinely factor-agnostic mechanism permits.

    Because they do not present the deficient factor to the immune system, they also
    remain effective once an inhibitor has made replacement therapy fail — which is
    what gives this entry's `Refractoriness to Factor Replacement` node a therapy at
    all. The class is not free of risk: rebalancing narrows the margin in the
    prothrombotic direction, and thromboembolic events have been reported in both
    programmes.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: fitusiran
      term:
        id: NCIT:C169984
        label: Fitusiran
    - preferred_term: concizumab
      term:
        id: NCIT:C166914
        label: Concizumab
    - preferred_term: marstacimab
      term:
        id: NCIT:C166436
        label: Marstacimab
  therapeutic_modality: SIRNA
  target_mechanisms:
  - target: Loss of the Propagation-Phase Thrombin Burst
    treatment_effect: RESTORES
    description: >-
      Lowering antithrombin or TFPI shifts the procoagulant-anticoagulant balance so
      that the thrombin generated by an intact extrinsic route is no longer quenched,
      recovering hemostatic thrombin output without repairing the tenase complex.
    evidence:
    - reference: PMID:40584300
      reference_title: "Marstacimab for the Treatment of Hemophilia A or B."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Marstacimab restores thrombin generation via the extrinsic pathway, bypassing intrinsic pathway deficiencies and offering prophylactic benefit independent of inhibitor status."
      explanation: >-
        States exactly the mechanism this edge asserts, and states that it operates by
        bypassing rather than repairing the intrinsic defect.
  - target: Refractoriness to Factor Replacement
    treatment_effect: BYPASSES
    description: >-
      Because no exogenous factor VIII or factor IX is administered, a neutralizing
      inhibitor has nothing to neutralize, so hemostatic benefit survives the state
      that abolishes the benefit of replacement therapy.
    evidence:
    - reference: PMID:37003287
      reference_title: "Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Subcutaneous fitusiran prophylaxis resulted in statistically significant reductions in annualised bleeding rate in participants with haemophilia A or haemophilia B with inhibitors, with two-thirds of participants having zero bleeds."
      explanation: >-
        Demonstrates efficacy specifically in the inhibitor population, i.e. in exactly
        the patients for whom factor replacement has been rendered ineffective.
  evidence:
  - reference: PMID:37003287
    reference_title: "Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, targets antithrombin to rebalance haemostasis in people with haemophilia A or haemophilia B, irrespective of inhibitor status."
    explanation: >-
      Names the modality, the molecular target, and the rebalancing mechanism, and
      states the factor-agnostic and inhibitor-agnostic scope that makes this a
      family-level rather than a member-level therapy.
  - reference: PMID:37003278
    reference_title: "Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fitusiran prophylaxis shows haemostatic efficacy in both haemophilia A and haemophilia B, and therefore has the potential to be transformative in the management of all people with haemophilia."
    explanation: >-
      The companion trial in the non-inhibitor population, establishing that efficacy
      spans both members independently of inhibitor status rather than only in the
      inhibitor setting.
  - reference: PMID:37646676
    reference_title: "Phase 3 Trial of Concizumab in Hemophilia with Inhibitors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Concizumab is an anti-tissue factor pathway inhibitor monoclonal antibody designed to achieve hemostasis in all hemophilia types, with subcutaneous administration."
    explanation: >-
      Establishes the second molecular route into the same class, and its explicit
      design intent of working across all hemophilia types.
  - reference: PMID:37646676
    reference_title: "Phase 3 Trial of Concizumab in Hemophilia with Inhibitors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among patients with hemophilia A or B with inhibitors, the annualized bleeding rate was lower with concizumab prophylaxis than with no prophylaxis."
    explanation: >-
      The explorer7 primary result, in a population spanning both members with
      inhibitors.
  notes: >-
    `therapeutic_modality` is single-valued and is set to SIRNA for the fitusiran arm;
    concizumab and marstacimab are MONOCLONAL_ANTIBODY. They are curated as one
    treatment because the mechanistic claim this root makes is about the shared
    rebalancing strategy rather than about either molecule, and splitting them would
    duplicate the family-level rationale twice. Split into two treatments if a curator
    later needs modality-precise querying. No `aso_details` block is present because
    fitusiran is an siRNA, not an antisense oligonucleotide.
clinical_trials:
- name: NCT03417102
  phase: PHASE_III
  status: COMPLETED
  description: >-
    ATLAS-INH. Randomised open-label phase 3 trial of monthly subcutaneous fitusiran
    prophylaxis versus on-demand bypassing agents in severe hemophilia A or B with
    inhibitors.
  target_phenotypes:
  - preferred_term: Joint hemorrhage
    term:
      id: HP:0005261
      label: Joint hemorrhage
  evidence:
  - reference: clinicaltrials:NCT03417102
    reference_title: "ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study was to determine the frequency of bleeding episodes in participants receiving fitusiran as prophylactic treatment of hemophilia compared to participants who were assigned to continue with their regular medication."
    explanation: >-
      Registry record for the pivotal inhibitor-population trial of the rebalancing
      class curated at this root.
- name: NCT03754790
  phase: PHASE_III
  status: COMPLETED
  description: >-
    ATLAS-OLE. Open-label long-term extension of fitusiran in hemophilia A or B, with
    or without inhibitors (281 participants). The enrolment criteria span both members
    of this family and both inhibitor states, which is why the trial is recorded at the
    root rather than on either member entry.
  evidence:
  - reference: clinicaltrials:NCT03754790
    reference_title: "An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To characterize the long-term safety and tolerability of fitusiran"
    explanation: >-
      Registry record for the long-term extension whose population spans hemophilia A
      and B with and without inhibitors.
- name: NCT04083781
  phase: PHASE_III
  status: COMPLETED
  description: >-
    explorer7. Phase 3 trial of daily subcutaneous concizumab prophylaxis in haemophilia
    A or B with inhibitors, reported in PMID:37646676.
  target_phenotypes:
  - preferred_term: Joint hemorrhage
    term:
      id: HP:0005261
      label: Joint hemorrhage
  evidence:
  - reference: clinicaltrials:NCT04083781
    reference_title: "Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B with inhibitors."
    explanation: >-
      Registry record confirming the trial population spans both members of the family
      in the inhibitor setting.
references:
- reference: PMID:20301578
  title: "Hemophilia A."
  tags:
  - GeneReviews
  findings: []
- reference: PMID:20301668
  title: "Hemophilia B."
  tags:
  - GeneReviews
  findings: []
discussions:
- discussion_id: hemophilia_root_scope_fxi_and_acquired
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Should factor XI deficiency and acquired hemophilia be curated as members of this
    root, given that MONDO places both beneath MONDO:0018660?
  attaches_to:
  - pathophysiology#Intrinsic Tenase Subunit Deficiency
  rationale: >
    MONDO's is_a descendants of MONDO:0018660 include congenital factor XI deficiency
    (MONDO:0012897 / MONDO:0020587, historically "hemophilia C") and acquired
    hemophilia (MONDO:0019139, with its A and B forms), but the MONDO textual
    definition of the same term restricts it to disease "due to factor VIII or IX
    deficiency". The ontology's hierarchy and its own definition therefore disagree,
    and this entry follows the definition.

    The exclusions are mechanistically motivated rather than merely conventional.
    Factor XI is upstream of the intrinsic tenase complex, not part of it, so factor XI
    deficiency does not instantiate this root's central mechanism node; it is
    autosomal rather than X-linked, so it fails the inheritance claim; and its bleeding
    phenotype is notoriously poorly correlated with factor level, so it fails the
    severity-by-residual-activity axis that is the second thing this root asserts.
    Acquired hemophilia fails a different test: its mechanism downstream of factor
    neutralization is genuinely this root's mechanism, but it is an autoantibody
    disease of adults with no germline lesion, so it is not an inherited coagulation
    factor deficiency at all. Notably, acquired hemophilia is closer to the
    "Alloimmune Inhibitor Response to Replacement Factor" node of this entry than to
    its trigger node.

    Recording rather than silently resolving this, because a future curator adding
    either entity will find MONDO asserting a parentage this entry declines.
  notes: >-
    If acquired hemophilia is curated later, the natural attachment is a shared
    mechanism module over factor-neutralization-mediated tenase failure, not
    membership in this root.
- discussion_id: hemophilia_b_leyden_mondo_placement
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    MONDO:0850054 (hemophilia B leyden) is not a descendant of hemophilia B or of
    hemophilia — should the ontology placement be reported upstream?
  attaches_to:
  - pathophysiology#Residual Factor Activity-Graded Hemostatic Reserve
  rationale: >
    MONDO:0850054 is asserted only as is_a MONDO:0002243 (hemorrhagic disease), so it
    sits outside the MONDO:0018660 subtree entirely, even though Orphanet classifies
    ORPHA:617930 as a subtype of a disorder and every clinical source treats Leyden as
    a form of hemophilia B. This entry curates it as a subtype on the strength of the
    clinical literature and flags the ontology gap rather than working around it by
    choosing a different term.

    The same subtree is missing the two symptomatic-female-carrier terms in a different
    way: MONDO:0015787 and MONDO:0015788 are descendants of MONDO:0018660, but dismech
    has no entry for either, and this root treats symptomatic carriership as part of
    the inheritance claim rather than as a subtype.
  notes: >-
    Candidate upstream report to MONDO: add is_a MONDO:0010604 (hemophilia B) to
    MONDO:0850054.
classifications:
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
📚

References & Deep Research

References

2
PMID:20301578
Hemophilia A.
No top-level findings curated for this source.
PMID:20301668
Hemophilia B.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 42 citations 2026-08-20T07:29:34.697008

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Hemophilia
  • MONDO ID: (if available)
  • Category: Genetic

Research Objectives

Please provide a comprehensive research report on Hemophilia covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Hemophilia: comprehensive disease-characteristics report

Scope and evidence note

This report concerns congenital hemophilia A and B, not acquired hemophilia A. Hemophilia A is factor VIII (FVIII) deficiency caused by pathogenic F8 variants; hemophilia B, or Christmas disease, is factor IX (FIX) deficiency caused by pathogenic F9 variants. Both are lifelong X-linked bleeding disorders. Acquired hemophilia A is instead an autoimmune FVIII-inhibitor disorder and belongs in the differential diagnosis rather than this genetic entry.

The evidence base combines disease-level resources, peer-reviewed human cohorts, trials, laboratory/in-vitro studies, and animal models. It is aggregated disease-level evidence, not an individual electronic health record. DOI URLs and publication dates are supplied because PMID metadata were not consistently exposed by the retrieved records; PMIDs are not guessed.

Feature Hemophilia A Hemophilia B
Causal gene / protein F8 / factor VIII deficiency (OpenTargets Search: hemophilia A,hemophilia B-F8,F9, deshpande2024adenoassociatedvirus–basedgene pages 1-2) F9 / factor IX deficiency (wang2024clinicalanalysisand pages 1-2, deshpande2024adenoassociatedvirus–basedgene pages 1-2)
Inheritance X-linked recessive inherited bleeding disorder (zhang2023moleculardiagnosisof pages 1-2, li2023f8geneinversion pages 1-2) X-linked recessive inherited bleeding disorder (wang2024clinicalanalysisand pages 1-2, arruda2021genetherapyfor pages 2-3)
Severity thresholds (shared) Severe <1%, moderate 1–5%, mild >5–40% factor activity (deshpande2024adenoassociatedvirus–basedgene pages 1-2, zhang2023moleculardiagnosisof pages 1-2) Severe <1%, moderate 1–5%, mild >5–40% factor activity (deshpande2024adenoassociatedvirus–basedgene pages 1-2, zhang2023moleculardiagnosisof pages 1-2)
Approximate prevalence / incidence Prevalence about 1 per 10,000 overall; incidence about 1:5,000 male births (chernyi2024recentadvancesin pages 1-3, arruda2021genetherapyfor pages 2-3) Prevalence about 1 per 60,000 overall; incidence about 1:30,000 male births (chernyi2024recentadvancesin pages 1-3, arruda2021genetherapyfor pages 2-3)
Common variant classes Intron 22 inversion is the major severe-HA lesion (~45% of severe cases); also intron 1 inversion, missense, nonsense, frameshift, deletions/insertions (guo2018spectrumofmolecular pages 1-2, zhang2023moleculardiagnosisof pages 1-2, zhang2023moleculardiagnosisof pages 2-3) Missense variants predominate; also nonsense, frameshift, deletions, deletion-insertions (wang2024clinicalanalysisand pages 1-2, wang2024clinicalanalysisand pages 8-9, wang2024clinicalanalysisand pages 7-8)
Inhibitor frequency About 20–30% alloantibody/inhibitor prevalence, especially in severe HA (arruda2021genetherapyfor pages 2-3) About 3–10% overall in reviews; 6.1% in one 2024 Chinese real-world cohort (arruda2021genetherapyfor pages 2-3, wang2024clinicalanalysisand pages 1-2)
Principal current prophylaxis Prophylaxis is standard of care; options include standard/extended half-life FVIII and subcutaneous emicizumab for HA (croteau20212021clinicaltrials pages 1-6, croteau20212021clinicaltrials pages 29-32) Prophylaxis is standard of care; options include standard/extended half-life FIX replacement (croteau20212021clinicaltrials pages 1-6, croteau20212021clinicaltrials pages 29-32)
Licensed gene therapy and key phase 3 outcome Valoctocogene roxaparvovec (Roctavian/BMN 270); phase 3 GENEr8-1 in 134 adults: FVIII activity rose by mean 41.9 U/dL at weeks 49–52, annualized bleeding rate fell 84.5% through 104 weeks, FVIII use fell 98.6%, mean FVIII 18.2 U/dL at month 36 (levien2024valoctocogeneroxaparvovec pages 2-3, levien2024valoctocogeneroxaparvovec pages 3-5) Etranacogene dezaparvovec (Hemgenix/AMT-061); phase 3 HOPE-B in 54 adults: mean FIX activity change 34.3 percentage points at 18 months, 96% stopped FIX prophylaxis in one review, and ~94% remained off prophylaxis at 3 years with FIX ~38.6 IU/dL at year 3 (anguela2024hemophiliaband pages 2-3, kaczmarek2024currentandemerging pages 5-5, anguela2024hemophiliaband pages 4-5)

Table: This table contrasts the core knowledge-base facts for congenital hemophilia A and B using only previously gathered evidence. It summarizes genetics, severity, epidemiology, inhibitor risk, current prophylaxis, and the main licensed gene-therapy outcomes for quick reference.

1. Disease information

Definition and classification

Hemophilia is failure of secondary hemostasis caused by inadequate FVIII or FIX activity. The accepted laboratory severity classes are severe, <1 IU/dL (<1%); moderate, 1–5 IU/dL; and mild, >5–40 IU/dL. Approximately 50–67% of patients with hemophilia A and 33–50% with hemophilia B have severe disease. Severe disease produces recurrent spontaneous bleeding, especially hemarthroses; moderate and mild disease more often manifests after trauma, dental work, or surgery. Women and girls can also be symptomatic owing to low factor levels, skewed X-inactivation, Turner syndrome, homozygosity/compound heterozygosity, or other unusual X-chromosome states. (deshpande2024adenoassociatedvirus–basedgene pages 1-2)

Identifiers and synonyms

Recommended knowledge-base mappings are:

  • Hemophilia A: MONDO:0010602; OMIM #306700; Orphanet ORPHA:448; ICD-10-CM D66; MeSH Hemophilia A. Open Targets independently identifies MONDO:0010602 and strongly associates it with F8. (OpenTargets Search: hemophilia A,hemophilia B-F8,F9)
  • Hemophilia B: MONDO:0010603; OMIM #306900; Orphanet ORPHA:98878; ICD-10-CM D67; MeSH Hemophilia B.
  • Umbrella synonyms: haemophilia, congenital hemophilia, hereditary factor deficiency.
  • A synonyms: factor VIII deficiency, classical hemophilia.
  • B synonyms: factor IX deficiency, Christmas disease.

The A/B entities should remain separate children beneath a congenital hemophilia parent. “Hemophilic arthropathy” is a complication, not a synonymous disease.

2. Etiology, risk, protection, and gene–environment interaction

Causal factors

The primary causes are germline loss-of-function or function-reducing variants in F8 or F9. The resulting low FVIII/FIX activity disrupts intrinsic-tenase amplification and thrombin generation. Open Targets gives F8–hemophilia A a high association score (0.918) supported by five literature evidence records, reinforcing that F8 is causal rather than merely correlative. (OpenTargets Search: hemophilia A,hemophilia B-F8,F9)

Genetic risk factors

  • In severe hemophilia A, F8 intron-22 inversion accounts for about 45% of cases; intron-1 inversion accounts for approximately 1–2%. Other lesions include missense, nonsense, frameshift, splice, small indel, exon/gene deletion, duplication, and complex structural variants. (zhang2023moleculardiagnosisof pages 1-2, li2023f8geneinversion pages 1-2)
  • In a 216-family molecular study, pathogenic F8 variants were found in 209 families (96.8%); Inv22 occurred in 89 severe families and Inv1 in five. Nonsense variants significantly increased inhibitor odds. (guo2018spectrumofmolecular pages 1-2)
  • In a 2024 hemophilia-B cohort, point variants constituted 84.2%, missense 63.2%, and nonsense 24.8% of identified F9 lesions; large deletions and truncating variants generally produce more severe disease and greater inhibitor risk. (wang2024clinicalanalysisand pages 8-9, wang2024clinicalanalysisand pages 7-8)
  • Family history is informative but not required. Only 30.3% of the 185-patient Chinese hemophilia-B cohort reported a family history, consistent with de novo variants, unrecognized maternal transmission, and incomplete family ascertainment. (wang2024clinicalanalysisand pages 1-2)

These are ordinarily germline, not somatic, disorders. Pathogenic variants should be exceptionally rare or absent from gnomAD/other population databases, but frequency alone cannot establish pathogenicity. Classification should use ACMG/AMP criteria, ClinVar/ClinGen evidence, phenotype, segregation, factor activity, RNA studies where appropriate, and functional assays. A VUS must not be used alone for predictive testing.

Environmental and treatment-related modifiers

No toxin, diet, infection, smoking exposure, or occupation causes congenital hemophilia. Environment chiefly modifies bleeding expression: trauma, surgery, contact sports, intramuscular procedures, antiplatelet/anticoagulant drugs, obesity-related joint loading, delayed treatment, and poor prophylaxis access increase morbidity. Conversely, regular prophylaxis, safe physical activity, normal body mass, dental care, vaccination, early bleed treatment, and multidisciplinary care protect against complications. In one real-world cohort, preventive therapy, absence of treatment delay and inhibitors, and avoidance of high-intensity episodic replacement correlated with better SF-36 scores. (wang2024clinicalanalysisand pages 1-2)

The major gene–environment interaction is genotype × treatment exposure in inhibitor formation. Null F8 genotypes create little endogenous antigen and raise alloantibody risk when therapeutic FVIII is introduced; intensive exposure, inflammation, surgery, treatment product, age, ancestry, and immune background can modify that risk. Severe hemophilia A develops inhibitors in roughly 20–30%, whereas reported hemophilia-B frequencies are approximately 3–10%. (arruda2021genetherapyfor pages 2-3)

No reproducible “protective allele” is established for routine clinical use. Higher residual factor expression from hypomorphic variants is functionally protective, while timely prophylaxis is the dominant modifiable protective factor.

3. Phenotypes

Core phenotype catalogue

  • Prolonged bleeding after injury/procedure — symptom/sign; congenital predisposition, but presentation may be neonatal through adulthood depending on severity; episodic and variable. Suggested HPO: Abnormal bleeding (HP:0001892) and Prolonged bleeding after surgery.
  • Spontaneous bleeding — severe disease, commonly beginning in infancy or early childhood as mobility increases; recurrent without prophylaxis. HPO: Spontaneous bleeding (HP:0001890).
  • Hemarthrosis — acute painful swelling, warmth, restricted movement, usually knees, ankles, and elbows; recurrent and strongly severity-dependent. HPO: Hemarthrosis (HP:0005261) and Joint swelling (HP:0001386). In a 2024 hemophilia-B cohort, 71.4% had joint bleeding and 64.4% of those had a target joint; lower-extremity joints predominated. (wang2024clinicalanalysisand pages 1-2)
  • Muscle/soft-tissue hematoma and easy bruising — episodic; can cause compartment syndrome, neuropathy, or anemia. Suggested HPO: Easy bruising (HP:0000978) and Intramuscular hematoma.
  • Mucosal/oral bleeding, epistaxis, hematuria and gastrointestinal bleeding — less characteristic than deep-tissue bleeding but clinically relevant. Suggested HPO: Epistaxis (HP:0000421), Hematuria (HP:0000790), and Gastrointestinal hemorrhage (HP:0002239).
  • Intracranial hemorrhage — uncommon but life-threatening, especially around birth, trauma, or untreated severe disease. HPO: Intracranial hemorrhage (HP:0002170).
  • Hemophilic arthropathy — chronic pain, stiffness, synovial hypertrophy, reduced range of motion, contracture, cartilage loss and subchondral bone damage after recurrent or subclinical hemarthrosis. Suggested HPO: Arthropathy (HP:0003040), Joint pain (HP:0002829), Joint contracture (HP:0001371) and Limitation of joint mobility (HP:0001376). Severe hemophilia can culminate in ankylosis and contractures. (chernyi2024recentadvancesin pages 1-3)
  • Laboratory abnormalities — low FVIII:C or FIX:C; typically isolated prolonged aPTT that corrects in a mixing study unless an inhibitor is present; normal platelet count and usually normal PT. HPO: Reduced factor VIII activity (HP:0003125) or Reduced factor IX activity, and Prolonged partial thromboplastin time (HP:0003645).
  • Inhibitors — laboratory/immune complication measured by Nijmegen-modified Bethesda assay; produce poor factor recovery and breakthrough bleeding.

Quality-of-life effects

Bleeding causes pain, exercise restriction, school/work absence, treatment anxiety, loss of independence, disability, and family financial burden. The 2024 cohort documented exercise limitation, missed school, injection distress, economic pressure and home-care burden. Diagnostic delay affected 34.6% and treatment delay 38.5%, demonstrating a real-world implementation gap. (wang2024clinicalanalysisand pages 8-9, wang2024clinicalanalysisand pages 7-8)

4. Genetic and molecular information

Genes and proteins

  • F8, Xq28, encodes coagulation factor VIII; HGNC symbol F8. FVIII circulates stabilized by von Willebrand factor and, once activated, acts as the FIXa cofactor.
  • F9, Xq27.1, encodes vitamin-K-dependent factor IX; HGNC symbol F9. Activated FIX combines with FVIIIa, calcium and phospholipid to activate factor X.

Normal circulating FVIII is low abundance (~1 nM) with an 8–12-hour half-life; FIX is ~90 nM with a 19–26-hour half-life. (arruda2021genetherapyfor pages 2-3)

Variant interpretation and structural abnormalities

Null variants—Inv22/Inv1, large deletion, nonsense, canonical splice and frameshift variants—usually cause severe disease through absent protein. Missense variants frequently retain partial activity and produce moderate/mild disease, although domain-specific exceptions occur. Copy-number variants require MLPA or genome-level detection; a reported partial 0.16-Mb F8 duplication combined with Inv22 preserved an intact transcript and produced no obvious phenotype, illustrating why structural context and RNA confirmation matter. (li2023f8geneinversion pages 1-2)

Routine molecular workflows now identify a causal variant in up to about 97% of hemophilia A families. Inversions should be tested explicitly; sequencing alone can miss them. Rare deep-intronic, regulatory, repetitive, mosaic, or complex rearrangements account for part of the residual unsolved fraction. (guo2018spectrumofmolecular pages 1-2, zhang2023moleculardiagnosisof pages 1-2)

Modifier genes and epigenetics

HLA class II, cytokine, immune-regulatory, and antigen-processing loci have been studied mainly as inhibitor-risk modifiers, but none currently replaces clinical/genotype risk models. Skewed X-chromosome inactivation is the most clinically important epigenetic phenomenon in symptomatic carriers. Disease-specific methylation, histone, single-cell, spatial-transcriptomic, lipidomic, or metabolomic signatures are not validated diagnostic features and should be recorded as research-only.

5. Environmental information

Congenital hemophilia has no infectious, toxic, radiation, pollution, dietary, alcohol, or smoking cause. Historically, plasma-derived concentrate exposure transmitted HIV, hepatitis B, and hepatitis C; modern recombinant products, donor screening and viral inactivation have greatly reduced this risk. Infections are complications of past treatment rather than etiologic agents.

Lifestyle influences morbidity. Appropriate low-impact exercise and physiotherapy improve strength and joint protection; obesity increases mechanical stress, cardiovascular risk and arthropathy burden. An active Netherlands trial, NCT05608863, is testing a two-year virtual coaching/group lifestyle program in approximately 30 overweight/obese people with bleeding disorders, measuring weight, bleeding, factor use and cardiometabolic outcomes. (NCT05608863 chunk 1)

6. Mechanism and pathophysiology

Upstream coagulation defect

The causal chain is:

F8/F9 pathogenic variant → deficient/dysfunctional FVIII or FIX → impaired intrinsic-tenase activity → inadequate factor-X activation and thrombin burst → weak fibrin clot and rebleeding → deep-tissue hemorrhage/hemarthrosis.

Suggested GO processes are blood coagulation (GO:0007596), hemostasis (GO:0007599), factor X activation, and fibrin-clot formation. Relevant cells include hepatocytes for FIX synthesis (CL:0000182), liver sinusoidal endothelial cells as principal FVIII-producing cells, platelets (CL:0000233), endothelial cells (CL:0000115) and synovial macrophages.

Downstream joint-damage cascade

Hemarthrosis → erythrocyte breakdown and iron/hemosiderin deposition → reactive oxygen species and chondrocyte apoptosis → macrophage/type-A synoviocyte activation → IL-1β, IL-6 and TNF-α → NF-κB, MMP and ADAMTS activation → synovial hypertrophy/pannus and cartilage degradation → VEGF-driven neovascularization and recurrent bleeding → subchondral bone loss, pain, contracture and disability. Human hemophilic-joint disease showed approximately fourfold elevated VEGF-A; candidate blood/tissue markers include SDF-1α, MMP-9, ferritin, D-dimer, COMP and collagen-turnover markers. (badulescu2024biomarkersinvolvedin pages 11-13, badulescu2024biomarkersinvolvedin pages 3-5)

TNF-α suppresses proteoglycan/collagen-II synthesis and promotes MMP-1, MMP-3, MMP-13 and ADAMTS4. IL-1β increases iron uptake by fibroblast-like/type-B synoviocytes. Reduced thrombin also diminishes PAR-1-mediated osteoblast proliferation; reduced osteoprotegerin with increased RANK/RANKL shifts remodeling toward osteoclast-mediated resorption. (badulescu2024biomarkersinvolvedin pages 5-6, badulescu2024biomarkersinvolvedin pages 8-10)

Suggested GO terms include inflammatory response (GO:0006954), reactive oxygen species metabolic process, angiogenesis (GO:0001525), extracellular-matrix disassembly, chondrocyte apoptotic process, and osteoclast differentiation (GO:0030316). Relevant cell terms include macrophage CL:0000235, fibroblast CL:0000057, chondrocyte CL:0000138, osteoblast CL:0000062, osteoclast CL:0000092, synovial fibroblast and vascular endothelial cell.

Immune involvement and profiling

Therapeutic factor may be internalized by antigen-presenting cells and presented to CD4 T cells, activating B cells and high-affinity neutralizing IgG. Mouse evidence implicates marginal-zone B cells in the initial anti-FVIII response. Immune-tolerance induction succeeds in approximately 60–80%, leaving a substantial refractory group. (chernyi2024recentadvancesin pages 3-4, badulescu2024biomarkersinvolvedin pages 10-11)

Proteomic/transcriptomic studies of arthropathy remain exploratory; no serum, synovial, proteomic, metabolomic or miRNA signature is sufficiently validated for routine diagnosis or prognosis. Much mechanistic evidence derives from synovectomy specimens, in-vitro synoviocytes, induced hemarthrosis in rodents/dogs, and small human biomarker cohorts, so causality and generalizability remain limited. (badulescu2024biomarkersinvolvedin pages 11-13, badulescu2024biomarkersinvolvedin pages 5-6)

7. Anatomical structures affected

The primary functional system is blood/coagulation. Bleeding secondarily affects:

  • Synovial joints: knees, ankles and elbows most characteristically; also hips, shoulders and wrists. Suggested UBERON: synovial joint UBERON:0002217, knee joint, ankle joint and elbow joint.
  • Skeletal muscle and connective tissue: hematomas and compartment syndromes.
  • Central nervous system: intracranial/spinal hemorrhage.
  • Mucosa, urinary tract and gastrointestinal tract: episodic bleeding.
  • Skeleton: subchondral bone erosion and osteoporosis downstream of chronic arthropathy.
  • Liver: source/therapeutic target for factor expression rather than a tissue injured by congenital deficiency; critical for AAV gene therapy monitoring.

Disease is not intrinsically lateralized. Individual bleeds may be unilateral, whereas chronic target-joint disease may be asymmetric or bilateral. Relevant subcellular locations include extracellular plasma/coagulation complexes, platelet membrane phospholipid surfaces, hepatocyte nucleus after gene transfer, and AAV episomes.

8. Temporal development

The molecular defect is congenital and lifelong. Severe disease may present with birth-related cephalohematoma or intracranial bleeding, post-circumcision hemorrhage, or bruising/hemarthrosis when crawling and walking begin. Moderate disease commonly emerges in childhood after trauma; mild disease may remain unrecognized until surgery or adulthood.

The untreated course is episodic bleeding with cumulative progressive damage: first hemarthrosis → recurrent bleed/target joint → chronic synovitis → established arthropathy, contracture and possible joint replacement. Bleeding can enter treatment-induced remission under effective prophylaxis, but the genotype does not spontaneously remit. Primary prophylaxis should begin early—expert guidance identifies before age two as the goal—to prevent rather than merely react to joint bleeding. (NCT07437404 chunk 1)

Critical windows are pregnancy/delivery planning, the neonatal period, initiation of mobility, the first factor-exposure days when inhibitors emerge, and early synovitis before irreversible cartilage loss.

9. Inheritance and population

Both A and B are X-linked recessive: hemizygous males are usually affected; heterozygous females show variable factor levels and bleeding. An affected male transmits the variant to all daughters and no sons; a heterozygous mother has a 50% chance of transmitting the variant in each pregnancy. Penetrance for a severe pathogenic variant is high in hemizygous males, but expressivity varies with residual activity, inhibitors, treatment and trauma. Anticipation is not a feature. Germline or parental somatic mosaicism can explain apparently de novo disease.

Estimates are approximately 1 hemophilia-A case per 5,000 male births and 1 hemophilia-B case per 30,000 male births; recent reviews estimate more than 1.1–1.2 million affected worldwide, roughly 400,000 with severe disease. Underdiagnosis and survival differences produce major regional variation. (chernyi2024recentadvancesin pages 1-3, deshpande2024adenoassociatedvirus–basedgene pages 1-2)

A 2024 African meta-analysis estimated hemophilia-A prevalence at 6.82 per 100,000 persons (95% CI 5.16–8.48), emphasizing ascertainment and access disparities. Population ancestry does not biologically restrict disease, but diagnosis and survival are strongly geography-dependent. Consanguinity can permit affected females when an affected father and carrier mother reproduce but is not required.

Among 106 mothers tested in a 2024 hemophilia-B cohort, 84.0% were molecular carriers; 27.7% had FIX 0.05–0.40 IU/mL and therefore a mild hemophilia-range phenotype. (wang2024clinicalanalysisand pages 8-9)

10. Diagnostics

Clinical and laboratory algorithm

  1. Suspect hemophilia from deep-tissue bleeding, hemarthrosis, disproportionate procedural bleeding, or family history.
  2. Obtain CBC/platelets, PT/INR, aPTT and fibrinogen. Congenital A/B typically shows normal PT/platelets with prolonged aPTT, although mild disease may have a normal screening aPTT.
  3. Perform an aPTT mixing study. Correction favors factor deficiency; failure to correct suggests an inhibitor, lupus anticoagulant, or anticoagulant drug.
  4. Measure one-stage and/or chromogenic FVIII:C and FIX:C; measure VWF antigen/activity because type 2N or type 3 von Willebrand disease can mimic hemophilia A.
  5. If response to factor is poor, quantify inhibitors with the Nijmegen-modified Bethesda assay.
  6. Assess joints with Hemophilia Joint Health Score, ultrasound/HEAD-US, and MRI when early synovitis/cartilage damage must be defined. In the 2024 cohort, HJHS correlated with HEAD-US-C (r=0.542, P<0.001). (wang2024clinicalanalysisand pages 1-2)

Differentials include von Willebrand disease, factor XI deficiency, combined FV/FVIII deficiency, vitamin-K deficiency, liver disease, disseminated intravascular coagulation, lupus anticoagulant, anticoagulant exposure, platelet disorders and acquired FVIII inhibitor.

Genetic testing

For hemophilia A, test Inv22 and Inv1, sequence all coding exons/splice boundaries, and use deletion/duplication analysis such as MLPA. For unresolved cases, add RNA analysis, long-read sequencing or WGS to detect deep-intronic and complex structural variants. A 2023 series used inversion assays, NGS and Sanger confirmation and found Inv22, Inv1, missense, nonsense and frameshift lesions; approximately 5% remained unresolved by then-current methods. (zhang2023moleculardiagnosisof pages 1-2, zhang2023moleculardiagnosisof pages 2-3)

For hemophilia B, sequence F9 plus CNV analysis. Targeted single-gene testing is generally more efficient than WES; WES may miss inversions, deep intronic lesions and CNVs. WGS/long-read sequencing is useful after negative comprehensive testing. CMA, karyotype and FISH are not routine unless a syndromic chromosome abnormality is suspected. Mitochondrial and repeat-expansion testing are not applicable.

Once the familial variant is known, offer cascade testing, factor assays in women and girls, prenatal diagnosis by CVS/amniocentesis, and preimplantation genetic testing for monogenic disease. One report used PGT-M, euploid unaffected embryo transfer, amniocentesis confirmation at 18 weeks, and neonatal FVIII testing. (bai2021casereportidentification pages 7-8)

11. Outcome and prognosis

With comprehensive care and safe prophylaxis, survival and quality of life can approach those of unaffected peers; without reliable therapy, fatal hemorrhage and lifelong musculoskeletal disability remain substantial. (marchesini2021recentadvancesin pages 10-12)

Major adverse prognostic factors are severe factor deficiency, intracranial hemorrhage, recurrent hemarthrosis/target joints, inhibitor development, delayed diagnosis or treatment, poor adherence/access, established arthropathy, chronic viral liver disease, and aging-related cardiovascular comorbidity. Inhibitors increase bleeding and complicate surgery. Cardiovascular disease prevalence in US patients has been reported as high as 15%, creating difficult antithrombotic decisions in older adults.

Factor activity, annualized bleeding rate, treated joint bleeds, target-joint count, HJHS, HEAD-US/MRI, inhibitor titer, factor recovery/half-life, pain, school/work participation and validated QoL tools are recommended outcomes. No omics-based prognostic biomarker is validated.

12. Treatment and current implementation

Standard strategy

Prophylaxis rather than on-demand-only therapy is standard for a severe bleeding phenotype. Individualize by age, bleeding history, joints, pharmacokinetics, activity, venous access, inhibitor status, preference and local access. Standard- and extended-half-life FVIII/FIX products replace the missing protein; Fc fusion, PEGylation and albumin fusion reduce infusion frequency. (croteau20212021clinicaltrials pages 29-32, croteau20212021clinicaltrials pages 1-6)

Adjuncts include desmopressin for responsive mild hemophilia A, tranexamic acid or aminocaproic acid for oral/mucosal bleeding, topical hemostasis and appropriately planned factor cover for procedures. Avoid desmopressin in hemophilia B. NSAIDs that impair platelets and intramuscular injections should generally be avoided or carefully managed.

Suggested NCIt intervention concepts include Coagulation Factor VIII, Coagulation Factor IX, Desmopressin, Tranexamic Acid, Prophylactic Therapy, Monoclonal Antibody Therapy, Gene Transfer Therapy, Physical Therapy, Synovectomy, and Joint Replacement.

Non-factor and inhibitor therapy

Emicizumab is a subcutaneous bispecific FVIIIa mimetic for hemophilia A with or without inhibitors, dosed weekly, every two weeks, or every four weeks. It reduces infusion burden but does not treat hemophilia B. Concurrent high-dose activated prothrombin-complex concentrate can cause thrombosis/thrombotic microangiopathy; laboratory assays also require specialist interpretation. (croteau20212021clinicaltrials pages 1-6)

Acute inhibitor bleeding is treated with recombinant activated FVII, activated prothrombin-complex concentrate, or appropriate factor where low-titer responsiveness remains. Immune-tolerance induction repeatedly exposes FVIII to eradicate inhibitors and succeeds in approximately 60–80%. (chernyi2024recentadvancesin pages 3-4)

Emerging “rebalancing” therapies suppress natural anticoagulants: fitusiran lowers antithrombin by siRNA; concizumab and marstacimab inhibit TFPI. Their attraction is subcutaneous prophylaxis across A/B and inhibitor states, but excessive rebalancing can cause thrombosis. Active programs also include FVIII mimetics such as Mim8. (joshi2024hemostatsinthe pages 22-23)

Gene therapy: 2023–2024 evidence

Etranacogene dezaparvovec (Hemgenix) is a single-dose liver-directed AAV5 vector carrying a codon-optimized hyperactive FIX-Padua transgene. FDA approval was 22 November 2022 and EU authorization 20 February 2023. In 54 HOPE-B participants, mean FIX activity change was 34.3 percentage points at 18 months; three-year levels were 41.5, 36.7 and 38.6 IU/dL at years 1–3, and 94% remained off prophylaxis at year three. Expression varied widely, and ALT elevations frequently required immunosuppression. (kaczmarek2024currentandemerging pages 5-5, anguela2024hemophiliaband pages 4-5, anguela2024hemophiliaband pages 2-3)

Valoctocogene roxaparvovec (Roctavian) is an AAV5 B-domain-deleted F8 gene therapy, approved in the United States in June 2023. In GENEr8-1 (134 adult men), FVIII rose by mean 41.9 U/dL at weeks 49–52, treated-bleed rate fell 84.5% through 104 weeks, factor use fell 98.6%, and mean FVIII was 18.2 U/dL at month 36. The year-over-year decline in FVIII is a major durability concern. (levien2024valoctocogeneroxaparvovec pages 2-3, levien2024valoctocogeneroxaparvovec pages 3-5)

Current limitations include adult-only eligibility, liver-health requirements, pre-existing anti-AAV antibodies, corticosteroid-treated transaminitis, uncertain decades-long durability, inability to redose the same capsid readily, variable expression, cost, and limited evidence in women, children, inhibitor patients and advanced liver disease.

Active/recent trials and real-world implementation

  • NCT06224907: phase 3 valoctocogene roxaparvovec in six Japanese adults with severe hemophilia A; excludes AAV5 antibodies, inhibitors and significant liver disease. (NCT06224907 chunk 2)
  • NCT07437404: recruiting phase 3 SCT800 recombinant FVIII in 36 previously untreated boys/men with severe A; inhibitor incidence is primary. (NCT07437404 chunk 1)
  • NCT05662319: active phase 3 subcutaneous fitusiran prophylaxis in 91 adolescent/adult males with severe hemophilia. (NCT05662319 chunk 3)
  • NCT03974113: phase 2/3 fitusiran in 32 boys aged 1 to <12 years. (NCT03974113 chunk 2)
  • NCT03754790: long-term phase 3 fitusiran safety/efficacy, 281 participants with A/B, with or without inhibitors.
  • NCT04083781/NCT04082429: phase 3 concizumab with inhibitors (134 participants) and without inhibitors (156).
  • NCT05685238: recruiting phase 3 long-term Mim8 study, 451 people with hemophilia A.
  • NCT06922045: phase 3 STSP-0601 for acute bleeds in 40 A/B patients with inhibitors; primary endpoint is 12-hour effective hemostasis. (NCT06922045 chunk 1)

13. Prevention

Primary prevention of the genotype is possible only through informed reproductive choice—not lifestyle modification. Offer nondirective genetic counseling, carrier/cascade testing, PGT-M, prenatal diagnosis and safe delivery planning. Population newborn screening is not standard; targeted neonatal factor testing is appropriate where family history or bleeding raises suspicion.

Secondary prevention means early diagnosis and prophylaxis before recurrent bleeding. Avoid traumatic delivery instrumentation where an affected fetus is possible; give vitamin K subcutaneously/orally or with careful pressure according to specialist protocol; assess suspected neonatal cranial bleeding urgently.

Tertiary prevention includes continuous prophylaxis, prompt bleed treatment, inhibitor surveillance, physiotherapy, safe exercise, weight and dental management, hepatitis A/B immunization, avoidance of platelet-impairing drugs, and specialist factor cover for surgery. Vaccination prevents treatment-associated hepatitis complications but does not prevent hemophilia itself.

14. Other species and natural disease

Natural X-linked FVIII/FIX deficiency occurs in dogs, cats, horses and cattle. Hemophilia A has been reported in Boxers, German Shepherd Dogs, German Shorthaired Pointers and mixed breeds. Hemophilia B is documented in at least 26 dog breeds and three cat breeds, including Cairn Terriers, Hovawarts, German Wirehaired Pointers and British Shorthairs. Reported animal F8/F9 lesions include missense substitutions, promoter nucleotide deletions and LINE-1 insertions. (dodds2022onehealthanimal pages 5-7, dodds2022onehealthanimal pages 11-12, dodds2022onehealthanimal pages 2-4)

Suggested taxa are Homo sapiens NCBI:9606, Canis lupus familiaris NCBI:9615, Felis catus NCBI:9685, Equus caballus NCBI:9796 and Bos taurus NCBI:9913. Breed VBO mappings should be attached where available. The condition is inherited, not infectious or zoonotic, and has no cross-species transmission.

Canine disease closely reproduces spontaneous bleeding, body size, immunity and clinical factor dosing, making dogs valuable for recombinant factor and gene-therapy studies. Purebred inbreeding can amplify pathogenic alleles, making veterinary carrier detection important.

15. Model organisms

  • F8- or F9-deficient mice: inexpensive, genetically tractable models for hemostasis, inhibitor immunology, AAV dose-ranging, CRISPR and tolerance studies. Limitations include small blood volume, species-specific immunity and less spontaneous joint disease than humans.
  • Hemophilia-A rats: more severe spontaneous bleeding and useful joint/trauma phenotypes; induced hemarthrosis produces C2M, C4M, CTX-II and PRO-C4 changes. (badulescu2024biomarkersinvolvedin pages 11-13)
  • Naturally affected dogs: large-animal models for pharmacokinetics, surgery, immune tolerance and durable AAV/lentiviral correction. Canine studies have demonstrated sustained phenotypic correction, but cost, colony size and species-specific immunity limit throughput. (dodds2022onehealthanimal pages 11-12)
  • Induced canine hemarthrosis: reproduces cartilage-turnover changes, including increased CTX-II and COMP. (badulescu2024biomarkersinvolvedin pages 11-13)
  • Nonhuman primates: mainly safety, biodistribution, liver transduction and dose studies; they generally lack the inherited bleeding phenotype.
  • Patient-derived endothelial/hepatic cells and iPSCs: useful for variant function, RNA defects, protein secretion and genome editing, but cannot reproduce whole-body bleeding or arthropathy.

A 2022 preclinical lentiviral study achieved stable, nearly lifelong normal-to-supranormal FVIII activity in hemophilia-A mice and normal-range activity in nonhuman primates, illustrating promise while not yet establishing human efficacy. These models also show that vector immunogenicity, pediatric liver growth and long-term genotoxicity are incompletely predicted by animals.

Key 2023–2024 conclusions and expert analysis

  1. The field has shifted from simply preventing fatal bleeding to near-zero bleeding, preserved joint health and low treatment burden through individualized prophylaxis.
  2. Gene therapy is clinically real, but not yet a universal cure: hemophilia-B FIX expression appears relatively stable through three years, whereas declining FVIII after Roctavian remains a central hemophilia-A problem. (kaczmarek2024currentandemerging pages 5-5, levien2024valoctocogeneroxaparvovec pages 3-5)
  3. Real-world inequity remains profound. Diagnostic/treatment delays and limited prophylaxis materially worsen joints and QoL, while lifetime treatment costs have been estimated at USD 20 million or more per patient in high-cost settings. (wang2024clinicalanalysisand pages 1-2, chernyi2024recentadvancesin pages 1-3)
  4. Joint disease is both degenerative and inflammatory. Iron-driven synovitis, cytokines, angiogenesis and abnormal bone remodeling explain why even subclinical bleeding can create progressive damage. (badulescu2024biomarkersinvolvedin pages 11-13, badulescu2024biomarkersinvolvedin pages 2-3)
  5. Molecular diagnosis should be comprehensive and structure-aware: inversion testing plus sequencing and CNV analysis approaches a 97% yield, while WGS/long-read/RNA methods address the residual unsolved fraction. (guo2018spectrumofmolecular pages 1-2, zhang2023moleculardiagnosisof pages 1-2)

Representative abstract wording

Recent reviews characterize hemophilia as an “X-linked lifelong congenital bleeding disorder” caused by insufficient FVIII or FIX and describe gene therapy as aiming for long-term endogenous factor expression. The 2024 gene-therapy literature calls Hemgenix’s authorization “a significant milestone,” while the Roctavian review describes its approval as “a landmark in HA therapeutics” but emphasizes the need for stable FVIII expression. These are expert-review statements rather than proof of permanent cure; the quantitative trial outcomes and durability limitations above should govern knowledge-base interpretation. (chernyi2024recentadvancesin pages 1-3, kaczmarek2024currentandemerging pages 5-5, levien2024valoctocogeneroxaparvovec pages 3-5)

References

  1. (OpenTargets Search: hemophilia A,hemophilia B-F8,F9): Open Targets Query (hemophilia A,hemophilia B-F8,F9, 43 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  2. (deshpande2024adenoassociatedvirus–basedgene pages 1-2): Saarang R. Deshpande, Keerthy Joseph, Jiayi Tong, Yong Chen, Allyson Pishko, and Adam Cuker. Adeno-associated virus–based gene therapy for hemophilia a and b: a systematic review and meta-analysis. Nov 2024. URL: https://doi.org/10.1182/bloodadvances.2024014111, doi:10.1182/bloodadvances.2024014111. This article has 30 citations and is from a peer-reviewed journal.

  3. (wang2024clinicalanalysisand pages 1-2): Wen Wang, Li Xu, Jingsheng Wu, Weiyong Liu, Jiao Jin, Jing Huang, Zhongjin Xu, Yali Huang, Bai Li, Yufeng Liu, Qing Zhang, Min Zhou, Jie Peng, and Qun Hu. Clinical analysis and quality of life survey of hemophilia b patients in the central and western regions of china. Frontiers in Pediatrics, May 2024. URL: https://doi.org/10.3389/fped.2024.1366990, doi:10.3389/fped.2024.1366990. This article has 3 citations.

  4. (zhang2023moleculardiagnosisof pages 1-2): Xialin Zhang, Kun Chen, Sicheng Bian, Gang Wang, Xiuyu Qin, Ruijuan Zhang, and Linhua Yang. Molecular diagnosis of hemophilia a and pathogenesis of novel f8 variants in shanxi, china. Global Medical Genetics, 10:247-262, Sep 2023. URL: https://doi.org/10.1055/s-0043-1774322, doi:10.1055/s-0043-1774322. This article has 3 citations.

  5. (li2023f8geneinversion pages 1-2): Shaoying Li, Jianchun He, Liming Chu, Shuai Ren, Wenzhi He, Xiaoyan Ma, Yanchao Wang, Mincong Zhang, Lingyin Kong, Bo Liang, and Qing Li. F8 gene inversion and duplication cause no obvious hemophilia a phenotype. Frontiers in Genetics, Feb 2023. URL: https://doi.org/10.3389/fgene.2023.1098795, doi:10.3389/fgene.2023.1098795. This article has 5 citations and is from a peer-reviewed journal.

  6. (arruda2021genetherapyfor pages 2-3): Valder R. Arruda, Jesse Weber, and Benjamin J. Samelson-Jones. Gene therapy for inherited bleeding disorders. Seminars in Thrombosis and Hemostasis, 47:161-173, Feb 2021. URL: https://doi.org/10.1055/s-0041-1722862, doi:10.1055/s-0041-1722862. This article has 29 citations and is from a peer-reviewed journal.

  7. (chernyi2024recentadvancesin pages 1-3): Nikita Chernyi, Darina Gavrilova, Mane Saruhanyan, Ezekiel S. Oloruntimehin, Alexander Karabelsky, Evgeny Bezsonov, and Alexander Malogolovkin. Recent advances in gene therapy for hemophilia: projecting the perspectives. Jul 2024. URL: https://doi.org/10.3390/biom14070854, doi:10.3390/biom14070854. This article has 48 citations.

  8. (guo2018spectrumofmolecular pages 1-2): Zhiping Guo, Linhua Yang, Xiuyu Qin, Xiue Liu, and Yaofang Zhang. Spectrum of molecular defects in 216 chinese families with hemophilia a: identification of noninversion mutation hot spots and 42 novel mutations. Clinical and Applied Thrombosis/Hemostasis, 24:70-78, Jan 2018. URL: https://doi.org/10.1177/1076029616687848, doi:10.1177/1076029616687848. This article has 26 citations.

  9. (zhang2023moleculardiagnosisof pages 2-3): Xialin Zhang, Kun Chen, Sicheng Bian, Gang Wang, Xiuyu Qin, Ruijuan Zhang, and Linhua Yang. Molecular diagnosis of hemophilia a and pathogenesis of novel f8 variants in shanxi, china. Global Medical Genetics, 10:247-262, Sep 2023. URL: https://doi.org/10.1055/s-0043-1774322, doi:10.1055/s-0043-1774322. This article has 3 citations.

  10. (wang2024clinicalanalysisand pages 8-9): Wen Wang, Li Xu, Jingsheng Wu, Weiyong Liu, Jiao Jin, Jing Huang, Zhongjin Xu, Yali Huang, Bai Li, Yufeng Liu, Qing Zhang, Min Zhou, Jie Peng, and Qun Hu. Clinical analysis and quality of life survey of hemophilia b patients in the central and western regions of china. Frontiers in Pediatrics, May 2024. URL: https://doi.org/10.3389/fped.2024.1366990, doi:10.3389/fped.2024.1366990. This article has 3 citations.

  11. (wang2024clinicalanalysisand pages 7-8): Wen Wang, Li Xu, Jingsheng Wu, Weiyong Liu, Jiao Jin, Jing Huang, Zhongjin Xu, Yali Huang, Bai Li, Yufeng Liu, Qing Zhang, Min Zhou, Jie Peng, and Qun Hu. Clinical analysis and quality of life survey of hemophilia b patients in the central and western regions of china. Frontiers in Pediatrics, May 2024. URL: https://doi.org/10.3389/fped.2024.1366990, doi:10.3389/fped.2024.1366990. This article has 3 citations.

  12. (croteau20212021clinicaltrials pages 1-6): Stacy E. Croteau, Michael Wang, and Allison P. Wheeler. 2021 clinical trials update: innovations in hemophilia therapy. American Journal of Hematology, 96:128-144, Nov 2021. URL: https://doi.org/10.1002/ajh.26018, doi:10.1002/ajh.26018. This article has 56 citations and is from a domain leading peer-reviewed journal.

  13. (croteau20212021clinicaltrials pages 29-32): Stacy E. Croteau, Michael Wang, and Allison P. Wheeler. 2021 clinical trials update: innovations in hemophilia therapy. American Journal of Hematology, 96:128-144, Nov 2021. URL: https://doi.org/10.1002/ajh.26018, doi:10.1002/ajh.26018. This article has 56 citations and is from a domain leading peer-reviewed journal.

  14. (levien2024valoctocogeneroxaparvovec pages 2-3): Terri L. Levien and Danial E. Baker. Valoctocogene roxaparvovec. Hospital Pharmacy, 59:254-263, Jan 2024. URL: https://doi.org/10.1177/00185787231222506, doi:10.1177/00185787231222506. This article has 1 citations and is from a peer-reviewed journal.

  15. (levien2024valoctocogeneroxaparvovec pages 3-5): Terri L. Levien and Danial E. Baker. Valoctocogene roxaparvovec. Hospital Pharmacy, 59:254-263, Jan 2024. URL: https://doi.org/10.1177/00185787231222506, doi:10.1177/00185787231222506. This article has 1 citations and is from a peer-reviewed journal.

  16. (anguela2024hemophiliaband pages 2-3): Xavier M. Anguela and Katherine A. High. Hemophilia b and gene therapy: a new chapter with etranacogene dezaparvovec. Blood Advances, 8:1796-1803, Apr 2024. URL: https://doi.org/10.1182/bloodadvances.2023010511, doi:10.1182/bloodadvances.2023010511. This article has 54 citations and is from a peer-reviewed journal.

  17. (kaczmarek2024currentandemerging pages 5-5): Radoslaw Kaczmarek, Wolfgang Miesbach, Margareth C. Ozelo, and Pratima Chowdary. Current and emerging gene therapies for haemophilia a and b. Haemophilia, 30:12-20, Mar 2024. URL: https://doi.org/10.1111/hae.14984, doi:10.1111/hae.14984. This article has 21 citations and is from a peer-reviewed journal.

  18. (anguela2024hemophiliaband pages 4-5): Xavier M. Anguela and Katherine A. High. Hemophilia b and gene therapy: a new chapter with etranacogene dezaparvovec. Blood Advances, 8:1796-1803, Apr 2024. URL: https://doi.org/10.1182/bloodadvances.2023010511, doi:10.1182/bloodadvances.2023010511. This article has 54 citations and is from a peer-reviewed journal.

  19. (NCT05608863 chunk 1): He-move-philia, Lifestyle Intervention for Patients With Hemophilia. Radboud University Medical Center. 2022. ClinicalTrials.gov Identifier: NCT05608863

  20. (badulescu2024biomarkersinvolvedin pages 11-13): Oana Viola Badulescu, Dragos-Viorel Scripcariu, Minerva Codruta Badescu, Manuela Ciocoiu, Maria Cristina Vladeanu, Carmen Elena Plesoianu, Andrei Bojan, Dan Iliescu-Halitchi, Razvan Tudor, Bogdan Huzum, Otilia Elena Frasinariu, and Iris Bararu-Bojan. Biomarkers involved in the pathogenesis of hemophilic arthropathy. International Journal of Molecular Sciences, 25:9897, Sep 2024. URL: https://doi.org/10.3390/ijms25189897, doi:10.3390/ijms25189897. This article has 15 citations.

  21. (badulescu2024biomarkersinvolvedin pages 3-5): Oana Viola Badulescu, Dragos-Viorel Scripcariu, Minerva Codruta Badescu, Manuela Ciocoiu, Maria Cristina Vladeanu, Carmen Elena Plesoianu, Andrei Bojan, Dan Iliescu-Halitchi, Razvan Tudor, Bogdan Huzum, Otilia Elena Frasinariu, and Iris Bararu-Bojan. Biomarkers involved in the pathogenesis of hemophilic arthropathy. International Journal of Molecular Sciences, 25:9897, Sep 2024. URL: https://doi.org/10.3390/ijms25189897, doi:10.3390/ijms25189897. This article has 15 citations.

  22. (badulescu2024biomarkersinvolvedin pages 5-6): Oana Viola Badulescu, Dragos-Viorel Scripcariu, Minerva Codruta Badescu, Manuela Ciocoiu, Maria Cristina Vladeanu, Carmen Elena Plesoianu, Andrei Bojan, Dan Iliescu-Halitchi, Razvan Tudor, Bogdan Huzum, Otilia Elena Frasinariu, and Iris Bararu-Bojan. Biomarkers involved in the pathogenesis of hemophilic arthropathy. International Journal of Molecular Sciences, 25:9897, Sep 2024. URL: https://doi.org/10.3390/ijms25189897, doi:10.3390/ijms25189897. This article has 15 citations.

  23. (badulescu2024biomarkersinvolvedin pages 8-10): Oana Viola Badulescu, Dragos-Viorel Scripcariu, Minerva Codruta Badescu, Manuela Ciocoiu, Maria Cristina Vladeanu, Carmen Elena Plesoianu, Andrei Bojan, Dan Iliescu-Halitchi, Razvan Tudor, Bogdan Huzum, Otilia Elena Frasinariu, and Iris Bararu-Bojan. Biomarkers involved in the pathogenesis of hemophilic arthropathy. International Journal of Molecular Sciences, 25:9897, Sep 2024. URL: https://doi.org/10.3390/ijms25189897, doi:10.3390/ijms25189897. This article has 15 citations.

  24. (chernyi2024recentadvancesin pages 3-4): Nikita Chernyi, Darina Gavrilova, Mane Saruhanyan, Ezekiel S. Oloruntimehin, Alexander Karabelsky, Evgeny Bezsonov, and Alexander Malogolovkin. Recent advances in gene therapy for hemophilia: projecting the perspectives. Jul 2024. URL: https://doi.org/10.3390/biom14070854, doi:10.3390/biom14070854. This article has 48 citations.

  25. (badulescu2024biomarkersinvolvedin pages 10-11): Oana Viola Badulescu, Dragos-Viorel Scripcariu, Minerva Codruta Badescu, Manuela Ciocoiu, Maria Cristina Vladeanu, Carmen Elena Plesoianu, Andrei Bojan, Dan Iliescu-Halitchi, Razvan Tudor, Bogdan Huzum, Otilia Elena Frasinariu, and Iris Bararu-Bojan. Biomarkers involved in the pathogenesis of hemophilic arthropathy. International Journal of Molecular Sciences, 25:9897, Sep 2024. URL: https://doi.org/10.3390/ijms25189897, doi:10.3390/ijms25189897. This article has 15 citations.

  26. (NCT07437404 chunk 1): Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.. Sinocelltech Ltd.. 2024. ClinicalTrials.gov Identifier: NCT07437404

  27. (bai2021casereportidentification pages 7-8): Haiyan Bai, Xia Xue, Li Tian, Xi Tong Liu, and Qian Li. Case report: identification of a de novo missense mutation in the f8 gene, p.(phe690leu)/c.2070c > a, causing hemophilia a: a case report. Frontiers in Genetics, Mar 2021. URL: https://doi.org/10.3389/fgene.2020.589899, doi:10.3389/fgene.2020.589899. This article has 5 citations and is from a peer-reviewed journal.

  28. (marchesini2021recentadvancesin pages 10-12): Emanuela Marchesini, Massimo Morfini, and Leonard Valentino. Recent advances in the treatment of hemophilia: a review. Biologics : Targets & Therapy, 15:221-235, Jun 2021. URL: https://doi.org/10.2147/btt.s252580, doi:10.2147/btt.s252580. This article has 86 citations.

  29. (joshi2024hemostatsinthe pages 22-23): Maithili Joshi, Zongmin Zhao, and Samir Mitragotri. Hemostats in the clinic. Bioengineering & Translational Medicine, May 2024. URL: https://doi.org/10.1002/btm2.10673, doi:10.1002/btm2.10673. This article has 8 citations.

  30. (NCT06224907 chunk 2): Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A. BioMarin Pharmaceutical. 2023. ClinicalTrials.gov Identifier: NCT06224907

  31. (NCT05662319 chunk 3): A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia. Sanofi. 2023. ClinicalTrials.gov Identifier: NCT05662319

  32. (NCT03974113 chunk 2): Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B. Genzyme, a Sanofi Company. 2020. ClinicalTrials.gov Identifier: NCT03974113

  33. (NCT06922045 chunk 1): Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients. Jiangsu BioJeTay Biotechnology Co., Ltd.. 2025. ClinicalTrials.gov Identifier: NCT06922045

  34. (dodds2022onehealthanimal pages 5-7): W. Jean Dodds. One health: animal models of heritable human bleeding diseases. Animals : an Open Access Journal from MDPI, 13:87, Dec 2022. URL: https://doi.org/10.3390/ani13010087, doi:10.3390/ani13010087. This article has 7 citations.

  35. (dodds2022onehealthanimal pages 11-12): W. Jean Dodds. One health: animal models of heritable human bleeding diseases. Animals : an Open Access Journal from MDPI, 13:87, Dec 2022. URL: https://doi.org/10.3390/ani13010087, doi:10.3390/ani13010087. This article has 7 citations.

  36. (dodds2022onehealthanimal pages 2-4): W. Jean Dodds. One health: animal models of heritable human bleeding diseases. Animals : an Open Access Journal from MDPI, 13:87, Dec 2022. URL: https://doi.org/10.3390/ani13010087, doi:10.3390/ani13010087. This article has 7 citations.

  37. (badulescu2024biomarkersinvolvedin pages 2-3): Oana Viola Badulescu, Dragos-Viorel Scripcariu, Minerva Codruta Badescu, Manuela Ciocoiu, Maria Cristina Vladeanu, Carmen Elena Plesoianu, Andrei Bojan, Dan Iliescu-Halitchi, Razvan Tudor, Bogdan Huzum, Otilia Elena Frasinariu, and Iris Bararu-Bojan. Biomarkers involved in the pathogenesis of hemophilic arthropathy. International Journal of Molecular Sciences, 25:9897, Sep 2024. URL: https://doi.org/10.3390/ijms25189897, doi:10.3390/ijms25189897. This article has 15 citations.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 16
Resolved 16
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 16
On topic 11
Off topic 1

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

  • DOI:10.1177/00185787231222506 (5 mentions) - Valoctocogene Roxaparvovec
  • shared terms: none

Weighed against this report's own most characteristic terms: disease, hemophilia, gene, bleeding, fviii, clinical, variant, inhibitor, genetic, treatment, severe, activity, include, prophylaxis, fix, molecular, phenotype, therapy, model, joint.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.